## content

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>Assignment of the Department of Dermatology Zurich University Hospital</td>
</tr>
<tr>
<td>2.</td>
<td>Mission Statement</td>
</tr>
<tr>
<td>3.</td>
<td>Team</td>
</tr>
<tr>
<td>4.</td>
<td>Patient Care including Laboratories</td>
</tr>
<tr>
<td>5.</td>
<td>Quality Management</td>
</tr>
<tr>
<td>6.</td>
<td>Research</td>
</tr>
<tr>
<td>7.</td>
<td>University Research Priority Project (URPP) Translational Oncology</td>
</tr>
<tr>
<td>8.</td>
<td>New Clinician-Scientists and Scientists</td>
</tr>
<tr>
<td>9.</td>
<td>Clinical research: The Zurich University Hospital Dermatology Clinical Trial Unit</td>
</tr>
<tr>
<td>10.</td>
<td>Research Foundations</td>
</tr>
<tr>
<td>11.</td>
<td>Medical Education / Teaching</td>
</tr>
<tr>
<td>12.</td>
<td>Museum of Wax Moulages</td>
</tr>
<tr>
<td>13.</td>
<td>Honoraries and Prizes</td>
</tr>
<tr>
<td>14.</td>
<td>Partners/Sponsors/Collaboration with Industry and Fund Raising</td>
</tr>
<tr>
<td>15.</td>
<td>Publications</td>
</tr>
</tbody>
</table>
Foreword

Dear Colleagues, friends, referring physicians, patients, partners and readers. It is my pleasure, in the name of my team of collaborators at the Department of Dermatology of the Zurich University Hospital, to provide you with an update of our recent activities within this biennial report.

Our department has set itself the aim of providing top quality patient care, research and education in the fields of dermatology, venerology and allergology, with a priority on innovation and leadership in dermatoncology, immuno-dermatology and allergology.

The time frame covered by this biennial report represents my 7th and 8th years chairing the Department. It reflects a period of perceptible increase in health-economic pressure, efforts to further improve efficiency and optimize processes of patient care without compromising high-level standards in ethics, teaching, quality of care and research.

In the last 2 years we have invested great effort into the in house promotion and recruitment and of talented clinicians, clinician-scientists and scientists as future leaders to further strengthen the Department. We have guaranteed the promotion of our focus on cutaneous oncology within a unique University Research Priority Program “Translational Oncology” financed with over 6 million Swiss Francs over 4 years under my direction in collaboration with 11 outstanding physicians and scientists from the University of Zurich (www.cancer.uzh.ch). We are part of an innovative public-private joint research program on cancer with Roche and in collaboration with the Department of Pathology at the Zurich University Hospital and the ETH. Finally we have launched of a priority program to promote inflammatory skin disease research, care and training, and the implementation of a departmental palliative-care program.

Modern infrastructure in healthcare contributes to efficiency and quality of care, as well as patient satisfaction. In an effort to modernize our infrastructure, our light and laser therapy unit was completely rebuilt so as to now offer optimal patient privacy, and a comfortable as well as practical environment for both our patients and employees. Our employees however are the premier guarantee of quality. In the last 2 years we have greatly profited from the recruitment of a new head of in-patient nursing in the person of Ms. K. Pauli, as well as 2 senior physicians and talented clinician-scientists returning to Europe from a fellowship in Harvard (Dr E. Guenova-Hötzeneker and PD Dr W. Hötzeneker). Likewise we have benefitted from the return of another talented clinician-scientist in the person of PD Dr A. Navarini from a fellowship in genomics and bioinformatics of inflammatory skin diseases at St John’s Institute of Dermatology/Kings College London. In 2013, a professorship funded by the “Verein für Hautkrebsforschung” was given to an outstanding scientist in the person of Prof. Mitch Levesque from the group of Prof. R. Dummer who is actively promoting our melanoma research and the development of an innovative Biobank of over 1,000 live primary tumor cell lines linked to genomic and clinical data.

In the same time-period four of our senior physicians (Drs J. Kamarachev, K. Kerl-French, S. Läuchli and W. Hötzeneker) and one senior scientist (Dr H.-D. Beer), were recognized by our University for their academic achievements and awarded the Venia Legendi by the University of Zurich. Also recognized was Prof. M. Maiwald with the reknown Götz Prize of the University of Zurich which honours outstanding, internationally visible academic achievement. In 2013, Prof. M. Maiwald and Prof. G. Hofbauer were both promoted to the status of Titulary Professors at the University of Zurich, and last but not least, Prof. O. Boyman who was an outstanding Swiss national Science Foundation Professor awardee at our Institution, and recipient of the Leo Pharma Research Foundation Gold award for his outstanding research in 2013, was nominated as Professor and Chairman of the Department of Clinical Immunology of the Zurich University Hospital as of 2014. Besides these newly recruited persons and awards, we are also proud of the successful board certification of 11 of our residents in training (Drs S. Gobbi, S. Gisler, A. Moser, M. Theiler, M. Barysch, J. Rinderknecht, C. Murer, M. Nägeli, N. Winterton, P. Dziunycz and R. Kasper).

With over 50 interventional clinical trials running currently in skin cancer and inflammatory skin diseases,
and in the context of an ongoing professionalisation of our clinical trial unit we are very fortunate that one of our board-certified physicians, Dr S. Goldinger, recently successfully completed a second board certification in Pharmaceutical Medicine. This is a rarity for us and a great addition to our Department. Dr Goldinger will be responsible for our clinical trials unit as of April 2015.

2013 was also a special year for the Departments Bruno Bloch Foundation which strives to raise money for supporting research and education in the Department. On the 7th of November 2013, the Foundation was able to raise 225,000 Swiss Francs as the result of a gala concert that it organized in the Zurich Tonhalle with the outstanding musicians Anne-Sophie Mutter and Lambert Orkis. The Department and the Bruno Bloch Foundation are extremely grateful to the above artists, the generous participants and donators for their generous support.

Finally and in 2014, the Department had the honor of hosting in Zurich and under the direction of Prof. R. Dummer and his team the Annual Meeting of the Society for Melanoma Research. The meeting was a great success with over 1,000 attendees and the presentation of outstanding innovative data, some of which was published the day after presentation in the New England Journal of Medicine!

The significant developments in our Department that I have highlighted in this “Foreword” give me confidence that – despite the current times of perceptible increase in health-economic pressure – we can look forward to the coming years with confidence. With an extremely dedicated team of which I am proud and to which I am thankful, we are ready to take on the next challenges in dermatology research and patient care.

With this selection of significant achievements realized in 2013–2014, I invite you in the name of my entire team to discover more in the following pages. Enjoy!

Prof. Dr med. Lars E. French
Chairman Department of Dermatology
University Hospital Zurich
1. Assignment of the Department of Dermatology
Zurich University Hospital

The Department of Dermatology of the Zurich University Hospital is devoted to provide sustained leadership in research, patient care and education in the fields of dermatology, venerology and allergology.

Our nationally and internationally recognized Department includes centers of excellence for skin cancer, inflammatory and allergic skin diseases as well as dermatological surgery. With a team of 47 specialized physicians we offer high-level patient care in all areas of dermatology, venerology and allergology in the context of our large out-patient ambulatory care clinic (Dermatologische Poliklinik), our in-patient dermatology service, our day care unit, and tertiary care referral clinics in a large number of specialty areas. These include: melanoma and difficult pigmented lesions, non-melanoma skin cancers, cutaneous lymphoma, bullous and autoimmune skin disease, medical dermatology, psoriasis, hair and scalp disease, occupational and contact dermatitis, dermatologic surgery, dermatopathology, and physical therapies (phototherapy, radiotherapy and laser therapy). Our research activities are focussed on basic and translational research with relevance to skin disease, primarily skin cancer and inflammatory skin disease. The efforts of our research groups are reflected by regular high level publications and a high cumulative yearly impact factor. Collaboration and networking with talented scientists and research groups within the University of Zurich, the ETH, collaborative networks such as the Zurich Cancer network, and other leading European Dermatology Centers considerably strengthens our research activities. Education is the third principle field of activity of our Department. In the past few years, the Department has focussed its resources on pre- and post-graduate training as well as on the development and maintenance of our innovative internet-based pre-graduate learning tool – DOIT (Dermatology Online with Interactive Technology in collaboration with the European Dermatology Forum).
2. Mission Statement

The top priorities of the Department of Dermatology USZ – in close collaboration with other Departments and Institutes of the USZ – are:

- to offer high quality individualized diagnosis and therapy of skin disease, as well as patient education in skin care and prevention of skin disease.

- to provide a high level of teaching and training in dermatology at the pre- and post-graduate level.

- to perform innovative basic and clinical research with the ultimate aim of contributing to improved patient-care.

- to foster constructive collaboration and networks with private practitioners as well as primary and secondary institutional care providers.

By fulfilling this mission we aim to position our department among the leading Dermatology Departments in Europe.
The department of Dermatology has a staff of 168 people including medical doctors, nursing staff, medical technical staff, laboratory staff, administrative staff and 40 research collaborators. Routinely, our Department hosts fellows and guests from abroad within its clinical and research activities.

### 3. Team

<table>
<thead>
<tr>
<th>Staff 2014 as per 31.12.2014</th>
<th>Full Time Equivalents %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chairman of the Clinic</td>
<td>31.6%</td>
</tr>
<tr>
<td>Vice-Chairman of the Clinic</td>
<td>26.3%</td>
</tr>
<tr>
<td>Physicians incl. Leading Medical Staff and Academicians</td>
<td>19.1%</td>
</tr>
<tr>
<td>Other Academic Specialists (IT/Project Manager)</td>
<td>11.3%</td>
</tr>
<tr>
<td>Nursing Team (incl. MTRA-Team)</td>
<td>10%</td>
</tr>
<tr>
<td>Laboratories Staff (incl. Photographer)</td>
<td>0.5%</td>
</tr>
<tr>
<td>Scientific Team (external funding via University of Zurich)</td>
<td>0.7%</td>
</tr>
<tr>
<td>Administration (incl. Clinical Manager)</td>
<td>0.7%</td>
</tr>
</tbody>
</table>

Laboratory staff
4. Patient Care including Laboratories

In the Swiss Health Service, inpatient dermatology is virtually exclusively available at the five university hospitals. In contrast, ambulatory care is offered both in the private sector and the public setting of university and state hospitals. As the largest academic dermatology center in Switzerland, the Department of Dermatology at the University of Zurich offers state of the art in-patient medical care for complex and rare skin problems. The department has very skilled surgeons that can perform complex surgical procedures and also histologically controlled procedures. In addition, our department is able to administer complex chemotherapeutic regimens or intravenous immunotherapy including antibodies and fusion molecules. Moreover, we provide an extensive spectrum of out-patient services including highly specialized consultations. Our department benefits from a large area referral base for these specialized activities as well as its own on-site histopathology laboratory.

Out-patient unit (Policlinic) & specialized ambulatory care clinics
PD Dr A. Cozzio and his team of dermatologists and specialized nurses treat over 30,000 patients upon referral in a total of over 72,000 consultations per year. In addition to the general out-patient clinics, patients can profit from international experts in their fields of dermatology and venereology in specialized out-patient clinics for autoimmune disorders, psoriasis, atopic eczema, acne and other severe dermatologic diseases.

In the day care clinic, a specialized team of doctors and nurses within the out-patient clinic treat patients with severe dermatologic diseases such as melanoma, cutaneous lymphoma, severe psoriasis, or autoimmune disorders. This innovative treatment center offers established infusion and injection treatments for these diseases, and, given its proximity to the clinical trial unit of the dermatology department, also performs up-to-date chemotherapeutic and immunologic anti-tumour treatments which have recently proven to be highly effective against melanoma and other skin cancers such as cutaneous lymphoma. This in-house interaction with one of the world-known research centers for skin cancers proves highly useful for rapid access to, and handling knowledge with medications with higher therapeutic efficacy in these diseases.

Certified Skin Tumor Center (Schwerpunkt Hautkrebs)
Our skin cancer center runs under the direction of Prof. R. Dummer with a team of expert skin cancer specialists (Prof. R. Braun, Prof. G. Hofbauer, PD Dr A. Cozzio, Prof. Dr M. Maiwald and Dr S. Goldinger), and is comprised of the following clinics. The pigmented lesion & skin cancer prevention clinic: this clinic runs under the direction of Prof. R. Braun and makes use of the most modern high tech equipment (confocal microscopy, skin surface videomicroscopy, dermoscopy, total body imaging) for the early detection of melanoma. The skin cancer clinic runs under the direction of Prof. R. Dummer and offers patients with skin cancer of different types (melanoma and non-melanoma skin cancer) highly professionalized treatment and follow-up as well as access to the most innovative clinical trials. The cutaneous lymphoma clinic runs under the direction of PD Dr A. Cozzio. In the above specialized clinics of our skin cancer center, patients have access to the best standards of diagnosis and care, a multi-disciplinary approach with tumor boards where required, and a broad variety of treatments including:
surgical interventions, physical treatment with special light sources or radiotherapy, photopheresis, topical immunomodulatory treatments, targeted cancer therapies and chemotherapy. Patients with certain types of cancer, especially melanoma are offered to have a molecular sub typing of their malignancy that is the basis for the selection of specific targeted therapies, such as Vemurafenib or Imatinib. These molecules have high response rates, even in metastatic melanoma. The Skin Cancer Center is supported by a world class clinical trial unit. This clinical trial unit is performing phase I, II and III trials. Most of them are international trials sponsored by pharmaceutical companies. The clinical trial unit plays a central role in the development of the second generation BRAF inhibitors and the second generation smoothened inhibitors. It was also the first clinical trial unit that used immune-modifying antibodies such as ipilimumab and very recently anti-PD 1 antibodies in the clinic in Switzerland. In the context of kinase inhibitors there are very recent data that suggest that MEK kinase inhibitors are powerful therapeutics in NRAS mutated metastatic melanoma. Innovative treatments are also investigating the use of topical substances such as resiquimod.

Investigator-initiated trials are very important tools to improve the data sets relevant for evidence-based medicine. In close cooperation with the EORTC, there were two investigator-initiated international trials in primary cutaneous T-cell lymphomas (mycosis fungoides), one for early stages comparing PUVA-therapy to a combination of PUVA and bexarotene and one for advanced stages investigating pegylated liposomal doxorubicin in tumor stage mycosis fungoides. Both trials finally have been closed successfully, and the intriguing results are available as decent publications.

Our inflammatory skin disease research group has been involved in several international trials sponsored by pharmaceutical companies too. Among molecules tested in psoriasis are antibodies against IL-17 and IL-17 receptor as well as small molecules targeting S1P1 and phosphodiesterase 4. Several innovative investigator-initiated trials are also being conducted in pyoderma gangraenosum, chronic urticaria and mastocytosis.

The ongoing clinical trials can be found on our website (http://www.dermatologie.usz.ch/HealthProfessionals/studien/Seiten/AktuelleStudien.aspx). On this link there are also listed the publications on our clinical research work.

Allergology Unit
The allergology unit of our department is a European certified (GALEN) center of excellence specialized in the diagnosis and treatment of acute and chronic allergic disease. Managed by Prof. P. Schmid and Prof. B. Ballmer-Weber, our allergy unit has developed a special focus on skin allergy, food allergy, drug allergy and desensitization protocols (specific immunotherapy), for example for life-threatening insect sting allergies.

Surgery Unit
Our surgical unit and its experienced team of dermatological surgeons (PD Dr S. Läuchli and Prof. J. Hafner) have developed a renown activity in general dermatological surgery with a focus on skin cancer surgery and chronic wound surgery. High-end techniques such as micrographic surgery (MOHS) for complex skin cancer cases, ablative laser treatments or fibrotic tissue shaving and skin transplantation for complex wounds are regularly performed with a high level of patient satisfaction in this unit.

Physical Treatment Unit – including Radiotherapy, Phototherapy & Laser Unit
This unit led by Prof. R. Dummer, Prof. G. Hofbauer and Dr L. Imhof is equipped with the latest physical therapy technologies, including UVA1 devices and a full laser and Intense Pulsed Light (IPL) platform. Recently, two modern X ray devices for superficial radiotherapy of skin cancer and selected refractory inflammatory diseases has been installed. Over 3,000 treatments are performed per year. The Department of Dermatology has a long-lasting interest in the application of laser technology. The Laser & Cosmetic therapy unit attracts patients from all over the world seeking treatment for cosmetic and skin conditions. We perform a full range of laser procedures, such as permanent hair removal, tattoo removal, laser treatments of vascular disorders, fractional resurfacing, fractional CO₂ and fractional erbium treatments, skin-tightening procedures and traditional CO₂ and erbium-resurfacing treatments. Additionally we perform numerous other treatments such as injections with botulinumtoxin, soft tissue fillers and chemical peels. In the last year under the direction of Dr L. Imhof the first study was performed comparing efficacy and safety of a Q-switched laser to a triple combination skin lightening cream in the treatment of solar lentigines. Dr L. Imhof collaborates with the Physics Institute of the ETH to further investigate the interaction of laser light and human skin tissue, and in an interdisciplinary manner with the plastic surgeons in the management of scar patients especially with burn scars.
**Weekday in-patient ward**
Our weekday in-patient ward under the direction of Prof. G. Hofbauer with a specialized multidisciplinary team of doctors and nurses provides a unique setting for complex topical or systemic therapy of refractory skin diseases, including the infusion of biologicals and chemotherapies. The team has 10 beds to provide rapid, complex in-patient workups and short in-patient therapies. This concept developed in 2007 has been highly successful and associated with a significant reduction in our overall mean length of in-patient hospital stay. This unit also offers extracorporeal photopheresis, an immunomodulatory treatment, to stem cell transplant recipients with graft-versus-host-disease, to lung transplant recipients suffering organ rejection, and to cutaneous lymphoma patients with three photopheresis units.

**In-patient clinic**
Our in-patient clinic with 26 beds, 8 of which are available for semi-private and privately insured patients is unique with respect to the medical expertise and the level of integrated medical and dermatological care that the highly specialized but also uniquely caring team of nurses and doctors offers. Under the direction of senior medical staff (Prof. L. French, Prof. R. Dummer, Prof. J. Hafner, Dr K. Schad) solutions are found for the management of the most severe forms of skin disease including complex autoimmune skin disease, skin cancer, therapy resistant atopic dermatitis and complex clinical presentations of skin disease for which an appropriate diagnostic and therapeutic approach needs to put in place. The concentrated medical expertise and friendly atmosphere makes this in-patient unit unique in its kind and regularly appraised by patients.

**Reorganization of dermatology nursing care**
Current and future circumstances have and will demand greater performance of all staff using fewer resources. Performance indicators and employee reviews have identified the need for action. Although synergies available through the various capacity factors at the DER E week clinic and DER D in-patient ward were exploited, the measures were not sufficient. Furthermore, the need for action is intensified due to the fact that nursing staff is in short supply. As a result, new models had to be developed to retain these employees at different stages in their lives. Both of the existing teams underwent a fundamental rethinking with respect to leadership structure, change management, staff-friendly employment terms, professional and quality assurance and development. The aim of the reorganization was to prepare the DER D and DER E teams to meet the requirements of the service mandate under the leadership of a departmental nursing director, taking into consideration maximum efficiency nursing and effectiveness. In particular, this required the existing teams to be less rigidly defined and cross-generation diversity management to be pursued in conjunction with the option of flexible staff shift schedules, such as those made possible by rotations. Staff found these changes to be supportive and enriching to their working environment.

The deployment of technical experts/issue-specific specialists and a nursing expert enabled professional quality to be assured and transient decreases in quality to be identified in good time. This included regular palliative care meetings, case supervision, nursing care meetings, mandatory further education sessions as part of the implementation concept, and monthly training sessions to develop professional skills. Professional development and quality assurance were continuously assessed and refined by systematically reviewing quality indicators such as CIRS reports, damage incident reports, vigilance reports, infection reports, fall events and patient feedback from the “We value your opinion” forms.

---

**Dermatopathology**
Essential for quality of the main focus of our clinical activities

**Dermatooncology**
– Center of Reference for Melanoma
– Center of Reference for Cutaneous Lymphoma
– MOHS (Micrographic Surgery of Skin Tumors)

**Immunodermatology**

---

**Statistics: Number of biopsies per year since 2012 – 2014**

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>Δ 2011 %</th>
<th>2013</th>
<th>Δ 2012 %</th>
<th>2014</th>
<th>Δ 2013 %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biopsies</td>
<td>28435</td>
<td>+ 0%</td>
<td>29316</td>
<td>+ 3%</td>
<td>30469</td>
<td>+ 4%</td>
</tr>
</tbody>
</table>
At the same time, several employees were trained to regularly work in the area of photopheresis at DER E, which had occasionally been difficult to arrange prior to the reorganization, either because there was no clear general framework in place or because there was relatively little interest among staff. Thanks to intensive staff training, the creation of staff-friendly general conditions and the integration of staff into process optimization activities, it was possible to bring about considerable improvement and introduce a degree of continuity in patient monitoring in conjunction with the facilitation of professional and qualitative development.

**Laboratory facilities**
The laboratory facilities of the department include labs devoted to routine lab procedures, and labs devoted to research. The department manages fully equipped dermatopathology, allergology, mycology, serology/venereology and 8 competitive skin disease and allergy research laboratories.

**Dermatopathology**
Our dermatopathology team examines and diagnoses 30,000 samples per year, provides testing of samples for formalin-fixed tissue and cryomaterial (frozen section), as well as specific immunopathological studies (immunohistochemistry, immunofluorescence). In collaboration with other teams we provide molecular biological studies (PCR) for pathogen-search or by suspicion of lymphomas. Our dermatopathology is a certified Teaching Centre and, in collaboration with the European Academy of Dermatology and Venerology (EADV) organises regular courses for residents in dermatology.

### Key Figures

<table>
<thead>
<tr>
<th></th>
<th>2013</th>
<th>2014</th>
<th>Change %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospital leaves - in patient setting (28.7% privately insured patients)</td>
<td>1,332</td>
<td>1,346</td>
<td>1.1%</td>
</tr>
<tr>
<td>Days of stay in-patient setting</td>
<td>10,090</td>
<td>10,416</td>
<td>3.2%</td>
</tr>
<tr>
<td>Mean Duration of stay of in-patients</td>
<td>6.3</td>
<td>6.5</td>
<td>3.2%</td>
</tr>
<tr>
<td>Casemix-Points</td>
<td>1,204</td>
<td>1,216</td>
<td>1.0%</td>
</tr>
<tr>
<td>Casemix-Index</td>
<td>0.904</td>
<td>0.904</td>
<td>0.0%</td>
</tr>
<tr>
<td>Consultations out-patient setting</td>
<td>73,404</td>
<td>71,834</td>
<td>-2.1%</td>
</tr>
<tr>
<td>Tax-points (chargeable)</td>
<td>16,275</td>
<td>16,568</td>
<td>1.8%</td>
</tr>
<tr>
<td>Revenues (medical service in mill. CHF)</td>
<td>41,643 mill. CHF</td>
<td>39,951 mill. CHF</td>
<td></td>
</tr>
<tr>
<td>Employees (full-time equivalents)</td>
<td>168</td>
<td></td>
<td></td>
</tr>
<tr>
<td>plus externally funded persons (third-party)</td>
<td>40</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Other routine laboratories
Besides dermatopathology the clinic is equipped with laboratories devoted to allergology, molecular diagnostics, mycology, and syphilis serology. These labs are run under the head of laboratory Dr P. Bosshard (together with Prof. P. Schmid-Grendelmeier in case of the allergology laboratory) and together analyze 12,000 patient samples per year. The allergology lab is very innovative as it was among the first using ISAC (Immuno Solid-phase Allergen Chip) in Switzerland. In the molecular diagnostics, specialized tests such as the T cell receptor clonality assay or a genital ulcer disease multiplex PCR are performed. The mycology lab is renown as kind of a reference laboratory, especially for dermatophyte infections.

The routine laboratories are currently in the process of being accredited according to ISO 15189:2012.

Research laboratories
The continued expansion of our research activities to now approx. 50 researchers was paralleled with an expansion of our research space. We now operate research laboratories in the top floor of our department at Gloriastr. 31, as well as across the street in Gloriastr. 30, and in 2014 we further expanded to a new campus in Schlieren at the outskirts of Zurich. The latter research campus will over the next years grow to finally house all biomedical research of the Zurich University Hospital. Our labs have all state of the art equipment to perform competitive research in the field of biochemistry, molecular biology, cell biology, immunology and allergy. For animal experiments we have access to a modern animal house at the University Hospital as well as in Schlieren. Our research labs are certified according to ISO standards and, for patient samples, comply with GMP guidelines. Yearly audits take place.

Interdisciplinarity within USZ
Several dermatologic disorders are associated with involvement of other vital organs, and thus best managed in a collaborative and interdisciplinary manner. Regular tumor boards, collaboration with the plastic surgeons and other departments of the USZ as well as immunology and rheumatology joint rounds contribute to guaranteeing an optimal standard of care.
5. Quality Management

Main Fields of activity

Our aim is to ensure that our organization and our services are consistent and of best possible quality. Our activities can be divided into the following four main components: quality planning, quality control, quality assurance and quality improvement. Our activities are not only focused on service quality, but also the means to achieve it. Our quality management therefore uses quality assurance and control of processes such as PDCA (plan-do-check-act or plan-do-check-adjust) to achieve more consistent quality. In order to achieve this goal, we intentionally chose a multidisciplinary approach in order to reach out to all groups of professions and to break barriers between those groups.

Our main focus of interest is the permanent improvement of the quality of care, the safety of our patients, and the satisfaction of our collaborators, referring physicians and most importantly patients.

In a recent enquiry we have asked more than 350 patients about their opinion. 97% of all patients would recommend us to a friend or a relative and 99.5% would get treated again at our facility.

We cover topics such as complaint management, Critical Incident Report System (CIRS) and surveys (patients, collaborators and referring physicians) among others. One of the central activities is the analysis and critical appraisal of all processes in the institution. In order to improve the standard of care we introduced a quality manual which is reviewed and updated on a regular basis. We use quality assurance and process control to achieve, maintain and permanently improve the quality of our care. We formulate annual goals, execute and follow up on them using an interdisciplinary approach breaking down barriers and involving all collaborators in this process.

The department is ISO 9001: 2008 certified by Swiss TS since 2011. This certificate does not only cover the Clinic but has been intentionally extended to research, education and our laboratories.

Our skin cancer centre is certified by the Deutsche Krebsgesellschaft (DKG) via Onkozert since 2011.

We are in charge of the certifications but consider the real challenge to make the step from simply fulfilling requirement catalogs to real quality management projects where everyone (collaborators, patients and referring physicians) can feel the improvement.

Results of the evaluation of the Department of Dermatology in 2013:

Would you recommend us to a friend or a relative?

<table>
<thead>
<tr>
<th>Yes</th>
<th>336</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>11</td>
</tr>
</tbody>
</table>

Would consider being treated at our institution in the future?

<table>
<thead>
<tr>
<th>Yes</th>
<th>345</th>
</tr>
</thead>
<tbody>
<tr>
<td>No</td>
<td>2</td>
</tr>
</tbody>
</table>

Team Certification and Accreditation:
Prof. Dr. Ralph Braun, Heiko Müller, Valérie Mucedero, Alice Meier
6. Research

We aim to continuously improve the quality of our service for patients and therefore critically depend on research and innovation. Our department is committed to the highest level of research in dermatology, and our achievement in this field – as judged by the cumulative impact factors for 2013 and 2014 (632 and 561) – positions us amongst the world’s leading Departments in the field.

Our research activities are primarily focused on basic, patient-oriented translational, and clinical research in: dermato-oncology, where we focus on the pathogenesis, early diagnosis and molecular targeted treatment of skin cancer, particularly in melanoma, cutaneous lymphoma, and non-melanoma skin cancers. Immunodermatology is also a research focus, especially innate immunity and T-cell biology in inflammatory skin diseases, notably psoriasis, neutrophilic dermatoses, cutaneous drug eruptions, and severe allergic adverse drug reactions. Allergology, emphasizing on drug and food allergies, and specific immunotherapy.

Aim of our research activities

- to promote high quality research with clinical relevance in the defined above mentioned fields of focus.
- intensive networking and collaboration with other institutes and departments at the Zurich University and ETH, as well as through active participation in networks such as the “Cancer Network Zurich” and “life sciences Zurich”.
- to support fellowships abroad in excellent research institutions, and maximize competitive research funding including that from the Swiss National Science Foundation (incl. SNF professorships).
- to create two endowed professorships in our Department in inflammatory skin disease and skin cancer research respectively, with the aim of recruiting or retaining leaders in these research fields to our department.
Key Figures and Highlights

Approximately 40 ongoing clinical trials on new therapeutic approaches in skin disease – corresponding to around 15% of all studies performed at the USZ.

Approximately 80 original and 30 review articles published in peer-reviewed journals in 2013 and 2014. Several high impact publications in interdisciplinary journals, such as:

- Rozati S, et al. Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, With Bilateral Intraocular Involvement and Infiltration to the CNS. J Clin Oncol 2014
- McArthur GA, et al. Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3); extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014

New intellectual property: in the last five years 7 patent applications have been submitted / registered.

SSS Weekend

In 2013 and 2014 we organized our 18th and 19th so called SSS weekend, which stands for Science, Sun and Snow. Approx. 50 our researchers participated at this meeting, which is held in the Schatzalp Hotel in Davos. At this meeting for one and a half days all of our young researchers present their work and update their progress, followed by intense discussions. The meeting also allows for a skiing day, a dinner and an evening cheese fondue, creating an atmosphere for the best possible scientific exchange.
Research Groups

**Group Members**

Prof. Dr med. Barbara Ballmer-Weber (group leader)
Dr med. N. Gräni
Dr med. C. Lang
Irène Cuhat

**Main Fields of Research**

Our research activities are focused on food allergy, in particular pollen related food allergy. We are particularly involved into the identification and molecular characterisation of important cross-reactive allergens, and the development of diagnostic and therapeutic methods based on recombinant allergens. Allergen based or component resolved diagnosis in food allergy is a major topic of our research group. Another important aspect of our research activity is risk assessment in food allergy in regard to genetic modified foods/novel foods but also threshold doses (minimal allergen doses to induce an allergic reaction) of plant and animal food allergens.

**Selected References**


**Group members**

PD Dr Hans-Dietmar Beer, PhD (group leader)
Dr Gerhard Strittmatter, PhD
Martha Garstkiewicz, PhD student
Jennifer Sand, PhD student
Serena Grossi, PhD student

**Main Fields of Research**

We are mainly interested in the role of keratinocytes, the main cell type of the epidermis, in immunity, inflammation and cancer development in the skin. Upon detection of stress signals in the epidermis, such as UVB irradiation, keratinocytes activate the protease caspase-1 resulting in pro-inflammatory cytokine secretion and inflammation. Our research focuses on the molecular mechanisms underlying caspase-1 activation as well as the down-stream events. Since caspase-1 and other family members are central regulators of inflammation and cell death, pathways critically involved in inflammatory skin conditions but also in cancer, research in our group focuses on the identification of novel targets for the treatment of these diseases.

**Selected References**


Group Members
Dr sc. nat. Philipp P. Bosshard (group leader)
Dr med. Martin Glatz
Dr sc. nat. Michael Walser
Stephanie Kieliger
Nada Juricevic

Main Fields of Research
Our research activities focus on sexually transmitted diseases (STI) and fungal infections.
Our main interest is in the development and evaluation of diagnostic tests and in clinical and epidemiological studies.

Selected References


Group Members
Prof. Dr med. Onur Boyman (group leader)
Dr Usrianeysh Hadis, PhD
Dr Antonios Kolios, MD
Dr Carsten Krieg, PhD
Dr Rodney Rosalia, PhD
Natalia Arenas Ramirez, PhD student
Noemi Bertel, MD student
Daniela Impellizzeri, PhD student
Céline Kaegi, MD student
Miro E. Raebel, MD student
Janine Woytschak, PhD student
Emerita Ammann Meier

Main Fields of Research
We are interested in approaches harnessing the stimulation of the immune system against cancer, including melanoma, or in dampening harmful immune responses such as seen in inflammatory and autoimmune diseases, including psoriasis, inflammatory bowel disease and type 1 diabetes. One of our research focuses deals with the modification of cytokines for improved immunotherapy.

Selected References

Group Leader
Prof. Dr. med. Ralph Braun

Main Fields of Research
Our main interest is non invasive diagnosis of skin cancer especially malignant melanoma. We use established techniques such as dermoscopy as well as new techniques in vivo laser scanning microscopy, dermoscopy. Due to different international research collaborations our patients benefit directly from the latest technological developments. Detecting skin cancer especially melanoma at early stages offers an unique opportunity to be cured.

Selected References
Braun, R. P., et al. (2012). Agreement of dermatopathologists in the evaluation of clinically difficult melanocytic lesions: how golden is the 'gold standard'? Dermatology, 224(1), 51 – 58

Selected References
Schlapbach C, Gehad A, Yang C, Watanabe R, Guenova-Hötzenecker E, Teague JE, Campbell L, Yawalkar N, Kupper TS, Clark RA. Human Th9 cells are skin-tropic and have autocrine and paracrine pro-inflammatory capacity. Sci Transl Med 2014 6(219): 219ra8

Group Members
PD Dr. med. Dr. sc. nat. Antonio Cozzio (group leader)
Dr. med. Emanuella Guenova-Hötzenecker (group leader)

Wolfram Hötzenecker, MD, PhD
Joanna Mangana, MD
Tabea Koch
Desislava Ignatova, PhD Student
Yung-Tsan Chang, PhD Student

Main Fields of Research
Our research activities focus on interactions between innate and adaptive immunity in cutaneous inflammation; Pathogenesis and therapy of skin tumours, cutaneous lymphoma & Merkel cell carcinoma; Development of new immune therapies and translational research.

Selected References
Group Members
Prof. Dr. med. Reinhard Dummer (group leader)
Mirjana Maiwald (-Urosevic), Prof., group leader lymphoma
Mitch Levesque, Prof., group leader melanoma
Simone Goldinger, MD
Sima Rozati, MD
Marieke Raaijmakers, MD
Daniel Widmer, Ph.D
Phil Cheng, Ph.D student
Daniel Hug
Jil Dreier

Study Nurses
Karen Meyer

Main Fields of Research
We have intensively studied the immune biology of cutaneous lymphomas, cutaneous melanoma and epithelial skin cancers. Based on the microenvironment of these tumors, we have established immune interventions in cell cultures and animal models. Translational research applies this new knowledge to our patients in order to provide effective treatment with best quality of life.

Selected References

IL-4 abrogates TH17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells. Proc Natl Acad Sci USA. 2015 112(7): 2163-8


Schlapbach C, Gehad A, Yang C, Watanabe R, Guenova-Hötze necker E, Teague JE, Campbell L, Yawalkar N, Kupper TS, Clark RA. Human Th9 cells are skin-tropic and have autocrine and paracrine pro-inflammatory capacity. Sci Transl Med 2014 6(219): 219ra8

Group Members
Prof. Dr. med. Lars E. French (group leader)
Dr. sc. nat. Emmanuel Contassot (principal investigator)
Dr. med. Dr. sc. nat. Atsushi Otsuka
Dr. sc. nat. Dragana Jankovic
Dr. sc. nat. Magdalena Kistowska
Samuel Gehrike (PhD student)
Roman Huber (PhD student)
Gabrielle Fenini (PhD student)
Tatiana Proust (Lab technician)

Main Fields of Research
Our objective is to identify and elucidate immunological and molecular mechanisms involved in the pathogenesis of skin diseases as a template for the discovery of novel therapeutic approaches. Our research activities are focussed on the mechanisms leading to innate immune responses in the skin upon exposure to pathogen and/or danger signals. We are particularly interested in the molecular events involved in Interleukin-1beta processing and secretion during the course of inflammatory dermatoses.

Selected References

———

Group Members
Prof. Dr. med. Jürg Hafner (Group Leader)
Dr. med. Claude Luder

Main Fields of Research
Oncologic dermatologic surgery
Dermatology and vascular medicine
– Wound healing
– Phlebology and angiology
– Compression therapy

Founding: JH Rahn Foundation, Zurich (supporting clinical research and post-graduate training in dermatologic surgery, phlebology and wound healing)

Selected References
Sippel K, Seifert B, Hafner J. Donning devices (foot slips and frames) enable elderly people with severe chronic venous insufficiency to put on compression stockings. Eur J Vasc Endovasc Surg. 2015 Feb;49(2): 221-9
Luder C, Dzunycz P, Omid N, Radetzki AL, Lang C, Hübner M, Hafner J. A compression kit of a stocking and superposed leggings is easy to done and dose adjustable. Eur J Vasc Endovasc Surg: Submitted
Group Members
Prof. Dr med. Günther FL Hofbauer (group leader)
Paola Atzei, PhD
Sandra Freiberger, PhD student
Johannes Neu, PhD student
Meisam Khorrami, pract. med.
Dr med. Piotr Dziunycz
Dr med. Chantal Bachmann
Dr med. Mosaab T. Mohanna
Elias Burri
Joana do Cabo, med. pract.
Sara Frauenfelder
Luca Funk
Emanuël Lengwiler
Anna Müller
Barbara Ruiys
Larissa Meier, med. pract.
Marina Schneider
Anais Schneider
Nadja Stenz
Daniel Stimpfle, med. pract.
Gilles Straub, med. pract.

Main Fields of Research
Our research activities are focused on squamous cell carcinoma of the skin. We have a special interest in organ transplant recipients as a high-risk population for the development of squamous cell carcinoma of the skin stemming from the combined effects of immunosuppression and ultraviolet light. Our research is thus focused on inflammation fighting skin cancer or contributing to the cutaneous carcinogenesis as well as on the role of UV damage in particular in conjunction with medication.

Selected References
Pain identifies squamous cell carcinoma in organ transplant recipients: the SCOPE-ITSCC PAIN study.


Group Members
PD Dr Wolfram Hötzecker (group leader)
Dr med. E. Guenova-Hötzecker, PhD
Dr med. N. Jaberg-Bentele
Dr med. E. Kretzschmar

Main Fields of Research
Our research activities are mainly focused on the function of the cutaneous immune system in health and disease. Thereby we have a special interest in the pathophysiology of severe cutaneous drug reactions. In that context we aim to identify the phenotype and function of resident immune cells of the skin in cutaneous drug reactions. Furthermore, we are interested in analyses of the impact of cellular stress (ROS) on tumor stroma and tumor formation as part of an ongoing collaboration with Prof. Dotto (Lausanne) and Dr Schatton (Boston).

Selected References


Group Members
PD Dr med. Thomas Kundig
Head of Research, Dept. of Dermatology
Pal Johansen, PD PhD
Ying Men-Wückers, PD PhD
Steve Pascolo, PhD
Martin Bachmann, Prof. Dr, PhD
Gery Jennings, PhD
Antonia Fettelschoss, PhD Postdoc
Franziska Zabel, PhD Postdoc

Associated members
(from Clinical Trials Center)
Gabriela Senti, PD MD
Fabian Tay, MD

Main Fields of Research
The major focus of research is the development and testing of new concepts of vaccination and immunotherapy for the treatment of allergies, infections, cancer and inflammatory diseases. Typically, treatment strategies are developed and tested in mice, but several strategies have been transferred to clinics and tested in randomized and controlled clinical phase I / II and currently also phase III trials.

Selected References

Group Members
Prof. Dr. nat. Mitch Levesque (group leader)
Dr sc. nat. Daniel Widmer
Dr sc. nat. Phil Cheng
Dr sc. nat. Ossia Eichhoff
Dr med. Verena Pautitschke
Mariike Raaijmakers
Theodora Chatzisaak
Andreas Dzung
Alice Langer
Melanie Maustrich
Mirka Schmid

Main Field of Research
We are interested in using functional genomics tools to understand the evolution of heterogeneity in skin cancer progression. In particular, we apply next-generation sequencing approaches to melanoma and other skin cancers. With access to one of the largest live-cell melanoma biobanks in the world, we have a unique resource in which to study the functional mechanisms of cellular heterogeneity and how these respond to various therapeutic regimens. Lastly, we are using the zebrafish model organism as a means to functionally validate novel genes from our genomics assays. The zebrafish is an emerging model organism that offers many advantages over traditional models according to the 3Rs (Replacement, Reduction, Refinement), and allows for a rapid functional assessment of the human cancer genome.

Selected References
https://scholar.google.ch/citations?user=kC5Qi6sAAAAJ&hl=en

Funding Sources
Verein für Hautkrebsforschung, Swiss National Science Foundation, Krebsliga Schweiz, Horizon 2020
Group Members
Prof. Dr. med. Mirjana Maiwald (-Urosevic)
Associate professor (Titularprofessorin)
Attending physician

Main Field of Research, Abstract

Cutaneous lymphomas are a heterogeneous group of extranodal lymphomas that are characterized by primary skin involvement. Recent discoveries of changes in molecular biology and immunology of these tumors have provided better understanding of the processes that govern lymphoma development in the skin. I investigated different biologic and immunologic aspects of cutaneous T- and B-cell lymphomas that may help develop more efficient and targeted therapeutic approaches. Despite a myriad of molecules that can be delivered by gene transfer, only cytokine gene transfer has entered clinical development in the field of primary cutaneous T- and B-cell lymphomas, where we are also involved. Furthermore, I am interested in dissecting immune pathways that are involved in tumor regression during different types of immunotherapy as well as other targeted therapies not only in cutaneous lymphomas but also in other skin cancers. As a counterpart of immune response stimulators, I am also keen to elucidate mechanisms governing immune system evasion by the tumor cells.

Main Fields of Research, Keywords
Cutaneous lymphoma
Gene therapy of skin cancer
Immunotherapy of skin cancer
Gene expression profiling of immune responses in skin cancer
Immune evasion mechanisms in skin cancer

Selected References


List of Publications in Pubmed
Group Members
Prof. Dr med. Peter Schmid-Grendelmeier (group leader)
Dr med. Meike Distler
Dr med. Matthias Drach
Dr med. Antonios Kolios
Dr med. Tatjana Maul
Dr med. Kirsten Schiesser
Dr med. Christina Weber
Selin Stäger
Suzanne Marti Wyss
Muriel Träxler

Main Fields of Research
Our research activities are focused on epidemiology, pathophysiology and treatment of allergic diseases, namely atopic dermatitis. We also investigate new regimens and therapeutic options in a variety of diseases, from pollen allergy to rarer ones such as mastocytosis and hereditary angioedema. Recently we have also started to implement, evaluate and improve educational tools to promote knowledge and training in allergic diseases.

Selected References
Since 2012 the Department of Dermatology plays a significant role within the URPP = University Research Priority program. The University Zurich has committed for this program a budget of CHF 6 million over a period of 4 years in order to follow designated research projects. This URPP is directed by Prof. Dr. Lars French, along with vice-director Prof. Conrad Basler and the scientific coordinator Prof. Dr. Maries van den Broek.

Thanks to significant developments in research, prevention and therapy, age-adjusted cancer death rates are finally decreasing for certain types of cancer including lung, colon, prostate, breast and uterus. Despite this encouraging development, too many people still suffer from the major effects of being diagnosed with cancer, from an important reduction in the quality of life and often still from a reduced life expectancy.

Both the University and the University Hospital of Zurich have inscribed cancer research and oncology — the branch of medicine that deals with cancer — amongst its top priorities. The funding of our URPP Translational Cancer Research clearly underscores the commitment of our University to promoting innovative cancer research and translation of the latter to the clinic through high quality science.

The URPP Translational Cancer Research is unique and original in that it unites an exceptional team of internationally recognized scientists and physician-scientists in the field of oncology and cancer research, and is determined to bridge the unfortunate gap in communication and collaboration between physicians and basic scientists to bring cancer research a step closer to translation into the clinic.

The research in the URPP Translational Cancer Research specifically focuses on the following four subprojects:

1. Oncogenic signal transduction pathways as targets for personalized tumor therapy
2. The interaction between cancer and the immune system
3. Tumor biopsy and live tumor cell biobank linked with clinical outcome data
4. Translation from bench to bedside

Additional information concerning the URPP Translational Cancer Research can be found on: www.cancer.uzh.ch
8. New Clinician-Scientists and Scientists

Dr med. Emmanuella Guenova-Hötzenecker
In 2013, Dr med. Emmanuella Guenova-Hötzenecker, PhD joined the University of Zurich and the Department of Dermatology as a recipient of the prestigious Marie Heim-Vögtlin Career Development Grant of the Swiss National Science Foundation. Dr Guenova-Hötzenecker graduated summa cum laude from the English Language School in Sofia, Bulgaria, and completed her medical school training mainly in Bulgaria and Germany. For her studies on the regulatory role of cytokines in cutaneous autoimmune diseases, Dr Guenova-Hötzenecker was awarded an MD and a PhD degree from the Eberhard Karls Universität, Tübingen, Germany and from the Medical University Sofia, Bulgaria. After receiving her board certification in dermatology, allergology and cutaneous oncology in Germany, Dr Guenova-Hötzenecker pursued cutaneous T cell lymphoma as her main interest in basic and clinical research and joined the Brigham and Women’s Hospital and the Harvard Medical School as a postdoctoral fellow and subsequently as a recipient of a Career Development Grant of the German Research Foundation. In the laboratories of the Harvard Skin Disease Research Center, led by Tom Kupper and Rachael Clark, Dr Guenova-Hötzenecker closely studied mycosis fungoides and Sézary syndrome, two common cutaneous T cell lymphomas. She discovered that malignant T cells are prone to express a distinct T cell phenotype, which could result in immune suppression and impaired pathogen defence in tumour patients.

In Zurich, Dr Guenova-Hötzenecker remains committed to high level translational research, with a clinical and research focus on immune regulatory mechanisms in skin diseases, cutaneous lymphoma and dermatopathology.

PD Dr med. Wolfram Hötzenecker
After completion of medical school at the University of Vienna 2001, I was involved as a PhD student in the working group of Prof. Elbe-Bürger at the Department Of Dermatology, Medical University Of Vienna for three years. During my doctorate I investigated the modulating effect of new topical immunosuppressants on the autochthonous immune system of the skin. Following the completion of my PhD degree I moved to the Department of Dermatology, Tübingen University Hospital, Germany, where I continued with research on oxidative stress and the immune system beside my clinical work. After completion of my specialist training, I joined the Harvard Medical School, Boston as a Research Fellow in Dermatology where, based on the results obtained in Tübingen, I studied the effects of ATF3 on skin tumors in greater detail. In 2013 I finally joined the University Hospital Zurich (UHZ), Division of Dermatology, where I am currently completing my second residency in Allergology & Clinical Immunology. My main focus of research is the pathogenesis of cutaneous drug reactions and drug allergy.

PD Dr med. & Dr sc. nat. Alexander Navarini
PD Dr med. Dr sc. nat. Alexander Navarini studied medicine in Basel and Paris and subsequently investigated neutrophil immune reactions and delayed-type adaptive immune responses in the laboratory of Professors Zinkernagel and Hengartner. His internships included internal medicine at Bruderholzspital Basel, infectious and tropical diseases at the Swiss Tropical Institute (Tanzania), and Dermatology and Venereology at the Department of Dermatology at the University Hospital Zurich, where he specialized in immunologic therapies with Biologics. He passed FMH and the European (UEMS/EBDV) board exams for dermatology and venereology in 2010. During a senior research fellowship at King’s College in London 2012-14, he reported the genetic architecture of severe acne as well as causal mutations for several pustular dermatoses including AGEP, palmoplantar pustulosis and acrodermatitis continua suppurativa Hallopeau. His clinical priority fields of expertise as attending physician is psoriasis, acne, hidradenitis suppurativa and eczema, and current research projects investigate severe acne, eczema, pyoderma gangrenosum and paediatric linear localized scleroderma.
Dr med. Martin Glatz

Previous positions
Moving from Graz to Zurich in 2009, I have finished my training in dermatology at the Department of Dermatology at the University Hospital in Zurich in 2012. From 2012 until 2014 I was a postdoctoral fellow at the Dermatology Branch at the National Institutes of Health (NIH) in Bethesda, MD, USA. Funded by the Swiss National Science Foundation and a research award from the intramural research program at the NIH, I investigated the influence of skin microbial communities on the development and course of atopic dermatitis.

Current position
By beginning of 2015 I have returned to Zurich and I am currently in training for the board certification for allergy and clinical immunology at the Allergy Unit at the Department of Dermatology as well as the Department of Immunology at the University Hospital of Zurich. The position at the Allergy Unit is funded by the CK Care Foundation.

Current function
My current function comprises patient care at both departments and research on atopic dermatitis. In particular, I am interested on the influence of the yeast Malassezia spp. on the course of this disorder. This research is supported by a research grant of the Deutsche Stiftung Dermatologie and the Arbeitsgemeinschaft Dermatologische Forschung.

Prof. Mitch Levesque, PhD

Professor Levesque received his PhD from Duke University in the United States in 2005 where he developed new computational tools to analyze large datasets. These included novel techniques to compare whole genome sequences as well as algorithms to reduce dimensionality in complex gene expression data. As a post-doctoral researcher in the lab of Nobel Laureate Prof. Christiane Nüsslein-Volhard at the Max Planck Institute, Professor Levesque applied some of these computational techniques to developmental pathways in the Zebrafish model organism. The main focus of his research in Zürich is to continue to generate new computational approaches to reducing large datasets relevant to translational cancer research, and to use Zebrafish to more quickly test the function of novel genes in an in vivo context.

Figure 1: Schematic of the evolution of melanoma heterogeneity (Widmer, Eichhoff, Dummer and Levesque 2015)
Clinical research is a major focus in an academic center like ours. It is essential to translate new basic research results into beneficial treatment regimens. Clinical trials today are performed in an increasingly regulated network uniting clinical, ethical, legal and economic aspects. Absolutely central to this is the respect of involved patients’ life, well-being, and integrity of all personnel involved (principles of good clinical practice).

In order to achieve this, a network of clinical trial specialists is necessary so that clinical trials can be integrated in the treatment strategy for the respective diseases.

The department of dermatology and the skin cancer unit have a long and successful record in this context. We are and have been a major research center for the development of targeted therapy and immunotherapy for skin cancers and immune-mediated skin diseases. The clinical trial unit of our center has extensive experience in early and late phases of clinical development (phase I-IV).

There are a number of phase I studies including first-in-human with gene-therapy approaches such as adeno-interferon-gamma (TG 1064) that further increased our broad expertise in clinical trials. In addition, we have even performed a highly complicated phase I trial in cooperation with our in-house department of nuclear medicine that allowed monitoring drug excretion after application of a radioactive dose of study drug (mass balance analysis).

In recent years, the clinical trial unit has worked with many molecules including:

- 3 BRAF-inhibitors
- 4 MEK-inhibitors
- 2 Anti-CTLA-4 antibodies
- 2 Anti-PD1 antibodies
- MDM2 inhibitors
- Somatostatin-analogs
- Antisense-BCL-2 Nucleotides
- Tyrosine kinase inhibitors including nilotinib, pazopanib, lapatinib and sorafenib
- Gene therapy including Allovectin-7 and adeno-interferon gamma and canary pox viral vectors
- Pan-kinase and Anti-VEGF inhibitors
- Monoclonal antibody-cytokine fusion proteins
- Vaccines
- Antimicrobial agents (taurolipid)
- PEG interferon
- Various Chemotherapies
- Hedgehog Pathway Inhibitors
- Histone-Deacetylase Inhibitors (HDAC)
- RXR Retinoids
- NAD+ biosynthesis inhibitors
- Purine Nucleosid Phosphorylase inhibitors
- Resiquimod
- IL-17A and IL-17R antibodies
- PDE4 inhibitors
- TNF-α antagonists
- IL-12/23 antibodies
- IL-1β antagonists
- IL1Ra soluble receptor
- Topical parathormone
- Topical Vitamin D3 analogons
- Anti-IgE antibodies

In the field of investigator initiated trials we have focused more on action studies. We were able to monitor the impact of multi kinase inhibitors in vivo by transcriptional analyses (large scale).

In addition, we focus on the development of different investigator initiated trials (IITs) for the treatment of orphan diseases of the skin or for subgroups of skin cancer patients with high medical need. Although limitations in space and resources in the face of increasing innovative trials and regulations currently limit further expansion, our clinical trial unit is today one of the leading clinical research centers in Europe.

---

**9. Clinical research: The Zurich University Hospital Dermatology Clinical Trial Unit**

Clinical research is a major focus in an academic center like ours. It is essential to translate new basic research results into beneficial treatment regimens. Clinical trials today are performed in an increasingly regulated network uniting clinical, ethical, legal and economic aspects. Absolutely central to this is the respect of involved patients’ life, well-being, and integrity of all personnel involved (principles of good clinical practice).

In order to achieve this, a network of clinical trial specialists is necessary so that clinical trials can be integrated in the treatment strategy for the respective diseases.

The department of dermatology and the skin cancer unit have a long and successful record in this context. We are and have been a major research center for the development of targeted therapy and immunotherapy for skin cancers and immune-mediated skin diseases. The clinical trial unit of our center has extensive experience in early and late phases of clinical development (phase I-IV).

There are a number of phase I studies including first-in-human with gene-therapy approaches such as adeno-interferon-gamma (TG 1064) that further increased our broad expertise in clinical trials. In addition, we have even performed a highly complicated phase I trial in cooperation with our in-house department of nuclear medicine that allowed monitoring drug excretion after application of a radioactive dose of study drug (mass balance analysis).

In recent years, the clinical trial unit has worked with many molecules including:

- 3 BRAF-inhibitors
- 4 MEK-inhibitors
- 2 Anti-CTLA-4 antibodies
- 2 Anti-PD1 antibodies
- MDM2 inhibitors
- Somatostatin-analogs
- Antisense-BCL-2 Nucleotides
- Tyrosine kinase inhibitors including nilotinib, pazopanib, lapatinib and sorafenib
- Gene therapy including Allovectin-7 and adeno-interferon gamma and canary pox viral vectors
- Pan-kinase and Anti-VEGF inhibitors
- Monoclonal antibody-cytokine fusion proteins
- Vaccines
- Antimicrobial agents (taurolipid)
- PEG interferon
- Various Chemotherapies
- Hedgehog Pathway Inhibitors
- Histone-Deacetylase Inhibitors (HDAC)
- RXR Retinoids
- NAD+ biosynthesis inhibitors
- Purine Nucleosid Phosphorylase inhibitors
- Resiquimod
- IL-17A and IL-17R antibodies
- PDE4 inhibitors
- TNF-α antagonists
- IL-12/23 antibodies
- IL-1β antagonists
- IL1Ra soluble receptor
- Topical parathormone
- Topical Vitamin D3 analogons
- Anti-IgE antibodies

In the field of investigator initiated trials we have focused more on action studies. We were able to monitor the impact of multi kinase inhibitors in vivo by transcriptional analyses (large scale).

In addition, we focus on the development of different investigator initiated trials (IITs) for the treatment of orphan diseases of the skin or for subgroups of skin cancer patients with high medical need. Although limitations in space and resources in the face of increasing innovative trials and regulations currently limit further expansion, our clinical trial unit is today one of the leading clinical research centers in Europe.
10. Research Foundations

Our department has two charitable foundations aimed at ultimately improving patient care by providing support for high quality research on the mechanisms of skin disease. The activities of the foundations are made possible by generous donations from patients and the public as well as industry.

Bruno Bloch-Stiftung

The Bruno Bloch Foundation [www.brunoblochstiftung.ch] was founded in 1935 by the widow of Prof. Bruno Bloch, Chairman of the Zurich Dermatology Department between 1916 and 1933; this foundation supports skin research and education activities specifically at the department of dermatology of the university of Zurich, including research on severe skin diseases such as inflammatory skin disease and skin cancer.

One of the traditions and highlights of the Bruno Bloch Foundation are the yearly Memorial Lectures which take place in February with over 200 Faculty Members and Students at the Zurich University Hospital. In 2014, the Bruno-Bloch Memorial Lecture was held by Professor Martin Röcken, Chairman in Dermatology of the Tübingen University, Germany. The lecture was devoted to psoriasis.

Charity Concert by Anne-Sophie Mutter

For the first time in 2013 the Bruno Bloch Foundation organized a Charity concert by with the exceptional contribution of Anne-Sophie Mutter. The collected funds served to finance the research for skin diseases and skin cancer of the Department of Dermatology at the Zurich University Hospital. Important donators supported this charity evening and made it possible to generate a substantial benefit in favor of the research. Given this success the Bruno Bloch Foundation will organize its second Charity evening in November 2015. For more information: www.brunoblochstiftung.ch

Bruno Bloch-Stiftung
für eine gesunde Haut

Gedächtnisvorlesungen:

Prof. U. Schnyder, 1991
Prof. E. Schöpf, 1992
Prof. O. Braun-Falco, 1993
Prof. E. Frenk, 1995
Prof. Th. Rufili, 1996
Prof. D. Petzoldt, 1997
Prof. R. Panizzon, 1998

Prof. H. Wolff, 1999
Prof. St. Büchner, 2000
Prof. H. Kerl, 2001
Prof. L.R. Braathen, 2002
Dr. G. Albrecht, 2003
Prof. D. Hohl, 2004
Prof. P. Elsner, 2005

Prof. R. Kaufmann, 2006
Prof. N. Yawalkar, 2007
Prof. M. Hertl, 2008
Prof. P. Itin, 2009
Prof. Th. Schwarz, 2010
Prof. A. Enk, 2011
Prof. M. Gilliet, 2012

Prof. T. Ruzicka, 2013
Prof. M. Röcken, 2014
Prof. A. Bircher, 2015
The Association for Research on Cancer of the Skin, founded in 2004, aims to coordinate and stimulate skin cancer research in Switzerland by supporting research in rare and severe forms of skin cancer (e.g., melanoma, cutaneous lymphoma). The board consists of Prof. Dr. R. Dummer, Zurich, Prof. Dr. L. French, Zurich, Prof. Dr. D. Hohl, Lausanne, Prof. Dr. R. Hunger, Berne, Prof. Dr. R. Kaufmann, Frankfurt, and Prof. Dr. W. Kempf, Zurich. It is currently chaired by Prof. R. Dummer. The current goal is to generate a substantial contribution to clinical and experimental skin cancer research in the department in Zurich and in other institutions in Switzerland.

Recently, the association has created an assistant professor position at The University of Zurich. Prof. Dr. Mitch Levesque, an internationally renowned melanoma researcher, will hold the position for at least 4 years starting from February 1st, 2014. His research activities involve developing new tools for understanding next generation sequencing data, and functionally testing novel melanoma mutations in the lab. In this context, he is using the zebrafish model organism to better understand the basic biology of cancer genes. In his new function, Prof. Levesque also manages the Dermatooncology biobank at the USZ, which provides a diverse collection of live cancer cells to collaborators for experimental research. These are fundamental research activities that are the basis for understanding melanoma progression and for future improvements in melanoma therapy.

11. Medical Education/Teaching

Medical education is crucial to guarantee a high level of professionalism of physicians and health care professionals. Our continued implication in education is reflected by

1. Education of students in the medical faculty of the university
2. Specialized training in Dermatology of resident physicians for board-certification in “Dermatology”, and in “Allergology and Immunology” for residents board certifying in allergology and clinical immunology
3. Continuing medical education of private practitioners – mainly dermatologists and allergologists, but also general practitioners and to a lesser extent other health care professions.

Education for students: Senior physicians of our department provide an introductory course for dermatology to 3rd year medical students, a yearly core course in dermatology (8-day Themenblock) to 4th year medical students, a new case-based thematic lecture series in the 6th year, and a practical training course in dermatology in the 6th year of the medical training curriculum at the University of Zurich. In complement to these ex-cathedra and bed-side teaching activities, medical students can benefit from web-based learning using an online platform (DOIT: Dermatology Online with Interactive Technology) developed by our Department under the direction of former Chairman (Prof. Dr med. Dr h. c. Günter Burg) in a close collaboration with several other dermatology departments (Basel, Bern, Lausanne, Jena and Stadtspital Triemli in Zurich and the European Dermatology Forum).

This platform is being continuously improved and currently exists in six languages and two further languages are scheduled. In 2009 the DOIT Platform was elected as the best internet based teaching platform and distinguished with the 50,000 Euro Medida Prize.

Resident physicians

The Department of Dermatology offers 22 residency positions for the 5 years of obligatory training required for obtaining swiss board certification in dermatology. Demand for residency training in our department is extremely high, with more than 150 applications for approximately 4 available positions per year. 2 training positions are also available for part of the board certification in immunology and allergology, as well as that of angiology. During their residency training in our department, residents benefit of the broadest offer in Switzerland, comprised of a rotation plan through 20 units and specialized clinics covering all subspecialties of dermatology and allergology, including dermatanocology, autoimmune skin disease, trichology (hair disease), dermatoesurgery, dermatopathology, physical skin therapy (radiotherapy, UV-therapy, laser), phlebology and others. Following interest from the German, Austrian and Swiss dermatological societies, the online platform for students (DOIT) is now being used as the base for the development of a paneuropean post-graduate online continuing medical education (CME) platform to be named DERMOKRATES. Our Department and Faculty are actively participating in this innovative project.

Continuing medical education (CME) / Postgraduate training for private practitioners

Our Department and Faculty offer 12 – 14 CME events and grand rounds per year, comprised in detail of – 6 half-day thematic CME events per year in the University Zurich Irchel (180 – 200 participants), and 6 – 8 grand rounds and interdisciplinary CME sessions, the latter co-organized with other medical disciplines at USZ. In addition to this, and as of 2007, 4 new CME’s per year entitled “Dermatology Update” have been added to our postgraduate teaching program, with the aim of providing a further platform for case presentations, short updates and an overview of important new publications in dermatology (Journal Club). In addition, in the context of the new “Schwerpunkt Entzündliche Hautkrankheiten”, founded in 2013, our Department organized in 2013 and 2014 four workshops on psoriasis for private practitioners (speakers: Prof. Dr Lars French, Dr Antonio Kolios and Dr Julia-Tatjana Maul). In order to promote the support of the Medical Practionor Assistances (MPA) four workshops took place under the lead of Dr Antonio Kolios and Dr Julia-Tatjana Maul. The aim of the latter workshops is optimize the support of the MPA of their practitioners themselves by preparing e.g. the PASI-score for the patients in advance to a consultation with the pratictonar.

An interesting and interactive exchange motivates us to continue this concept of medical education at a broader range.
Zürcher Dermatologische Fortbildungstage
The “Zürcher Dermatologische Fortbildungstage” were launched in 2011 and immediately proved to be very successful as reflected by the feedback and the number of participants – mainly practicing dermatologists – which are regularly over 200. The four day intensive continuing medical education event offers a mixture of plenary “state of the art” lectures, hand-on workshops at the Department of Dermatology, and a half-day “What’s new” session. The latter provides the participants an overview of the most important developments in the preceding year. In 2014, the “Zürcher Dermatologische Fortbildungstage” took place in the Zurich Convention Center from June 25 – 28, 2014.

Overview 2013 and 2014

Continuing medical education 2013

<table>
<thead>
<tr>
<th>Subject / Title</th>
<th>Type of education</th>
<th>Date</th>
<th>Organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>In Memoriam Prof. Urs W. Schnyder</td>
<td>Dermatology</td>
<td>March 21, 2013</td>
<td>PD Dr. A. Cozzio, Prof. L. French</td>
</tr>
<tr>
<td>Reihe Regionale Dermatologie: Dermatosen am Kopf</td>
<td>Dermatology</td>
<td>April 11, 2013</td>
<td>PD Dr. A. Cozzio</td>
</tr>
<tr>
<td>Interdisziplinäre Versorgung von Hautkrebspatienten:</td>
<td>Interdisciplinary</td>
<td>May 16, 2013</td>
<td>Prof. R. Dummer</td>
</tr>
<tr>
<td>Von der Chirurgie zur medikamentösen Therapie</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Geburtstags-Symposium Prof. Dr. Brunello Wüthrich:</td>
<td>Allergology</td>
<td>September 26, 2013</td>
<td>Prof. P. Schmid-Grendelmeier, Prof. B. Ballmer-Weber</td>
</tr>
<tr>
<td>Ein Leben für Allergiker</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dermatochirurgie LIVE</td>
<td>Dermatology</td>
<td>December 5, 2013</td>
<td>Prof. J. Hafner, Dr. S. Läuchli</td>
</tr>
</tbody>
</table>

Continuing medical education 2014

<table>
<thead>
<tr>
<th>Subject / Title</th>
<th>Type of education</th>
<th>Date</th>
<th>Organisation</th>
</tr>
</thead>
<tbody>
<tr>
<td>20 Jahre Extrakorporale Photopherese am USZ</td>
<td>Dermatology</td>
<td>January 16, 2014</td>
<td>Prof. G. Hofbauer</td>
</tr>
<tr>
<td>News and Views: Entwicklungen in der Dermatologie</td>
<td>Dermatology</td>
<td>April 10, 2014</td>
<td>PD Dr. A. Cozzio</td>
</tr>
<tr>
<td>Interdisziplinäre Versorgung von Hautkrebspatienten:</td>
<td>Interdisciplinary</td>
<td>May 15, 2014</td>
<td>Prof. R. Dummer</td>
</tr>
<tr>
<td>Hautkrebstherapie: Neue Medikamente für den Kliniker</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dermatosen</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7. Internationaler Dermatoskopie Kurs</td>
<td>Dermatology</td>
<td>September 29, 2014</td>
<td>Prof. R. Braun</td>
</tr>
<tr>
<td>Dermatochirurgie LIVE</td>
<td>Dermatology</td>
<td>October 30, 2014</td>
<td>Prof. J. Hafner / Dr. S. Läuchli</td>
</tr>
</tbody>
</table>

Zürcher Dermatologische Fortbildungstage 2014;
Dr. S. Goldinger, Session “What’s New in Dermatooncology”
12. Museum of Wax Moulages

The Museum of Wax Moulages celebrated its 20th anniversary in 2013 with the opening of the new exhibition “Bodies in wax or pixel?”

In 1993 it was the first modern museum that focused on historical three dimensional wax replicas of skin and surgical diseases. In the meantime the Museum became an internationally leading institution concerning the presentation of wax moulages for the public, the use of the historical objects for research in medical history, and the use of the uniquely realistic models for teaching Dermatology at the University.

A professional preservation of the 2000 wax moulages must be the fundament for working with these fragile documents of historical patients. In 2013 a two years project in collaboration with the Bern University of the Arts (BUA) and the Swiss Institute for Art Research in Zurich resulted in the publication of detailed guidelines for the conservation and restoration of wax moulages in general and with special focus on Zurich. On the basis of this work a new depot for the collection was provided by the University Hospital permitting an exemplary storage of the collection. Sabina Carraro as restorer and Michael Geiges as curator advise several institutions with collections of wax moulages in Switzerland and abroad.

One focus for the future will be the completion of the teaching collection with new moulages. Concerning the historical moulages there is a conflict of preserving the fragile objects and the risk of damage when showing them to the public in the museum as well as in other exhibitions as loan collection. Therefore, as a next step, our interest also focuses on duplicating wax moulages without touching them. After first experiments in collaboration with Inspire (Swiss Federal Institute of Technology Zurich) in 2013, we started a new research project in collaboration with the BUA in 2014 on 3D-Scanning and 3D-Printing of wax moulages.

The new exhibition in the Museum demonstrates our three main fields of interest:

■ teaching: with the teaching collection referring consistently to the Swiss Catalogue of Learning Objectives for the Medical Training

■ history of dermatology and medicine: with moulages documenting medical research, progress and dead ends, and moving stories about patients that have been treated in the first half of the 20th Century at the Dermatology and the Surgery Clinic in Zurich.

■ the object itself: with an illustrated history of the use of the medical moulage in academic teaching, the damage symptoms that occur over time with the need for professional conservation and restoration and the idea of producing touch free duplicates.

The Museum of Wax Moulages was Cofounder of the internationally active Working Group for Wax Moulages in Berlin in 2013 and helps building up an international network of Institutions and persons that are in concern of wax moulages. The Museum of Wax Moulages is also engaged in collaboration with the museum of the University of Zurich and was in 2013 Cofounder of the Coordination Group for Museums of the University. The Museum is a member of the Swiss and International Council of Museums and participates actively in the museum scene of Zurich. The museum is well frequented by a broad public and offers guided tours. About half of the visitors have a medical background or visit the museum as part of their formation (e.g. care, cosmetics). An important highlight was again the traditional "Lange Nacht der Museen" when the museum opens its doors until 2 am in the morning with up to 600 visitors in September 2014.

For information about opening times of Museum of Wax Moulages of the University Hospital and the University of Zurich please consult: www.moulagen.ch

Michael L. Geiges, Curator
13. Honors and Prizes

Special Honors

Promotions

Klinikdirektor (Chairman)
Prof. Dr med. Onur Boyman has been elected to be the chairman of the “Klinik für Immunologie USZ” as per February 1st, 2014.

Titularprofessur
PD Dr med. Günther Hofbauer and PD Dr med. Mirjana Maiwald were promoted to the rank of “Titular Professor”.

Assistant professorship
Prof. Dr Mitchell Levesque was awarded an assistant professorship for six years; his position is financed by the Verein für Hautkrebsforschung. He is working in close collaboration with the research group of Prof. Dr med. Reinhard Dummer.

Venia Legendi
■ PD Dr Hans-Dietmar Beer
■ PD Dr med. Wolfram Hötzenecker
■ PD Dr med. Jivko Kamarachev (mainly dermatopathology)
■ PD Dr med. Katrin Kerl (mainly dermatopathology)

Oberärzte
■ Dr med. Marjam Barysch (Oberärztin i.V.)
■ Dr med. Simone Goldinger (mainly dermatotology) (in addition: Dr S. Goldinger has graduated to the “Facharztstitel of “Pharmazeutische Medizin”)

Prizes
■ Prof. Dr med. Onur Boyman received the Gold Award 2013 of the LEO Pharma Research Foundation in the field of treatment of psoriasis, autoimmune and inflammatory diseases and cancer
■ Dr med. Simone Goldinger received the Pierre Fabre Skin Cancer Award 2013 that has been awarded for the first time by the “Verein für Hautkrebsforschung” for the treatment of melanoma patients with metastasis of the brain
■ PD Dr med. Wolfram Hötzenecker received the Louis-Widmer Fonds Prize 2013 (SGDV Annual Meeting, Basle 2014)
■ Prof. Dr med. Mirjana Maiwald received the Götz-Preis 2013 for her contribution to skin cancer research in the field of cutaneous lymphoma

Named Lectures
Prof. Dr med. Lars French: René Touraine Lecture, International Investigative Dermatology Meeting, Edinburgh, Scotland, 2013

Further promotions
Prof. Dr O. Boyman who was an outstanding Swiss national Science Foundation awardee at our institution was nominated as Professor and Chairman of the Department of Clinical Immunology of the Zurich University Hospital as of 2014.

Prof. Dr med. Peter Schmid-Grendelmeier was elected per July 1st, 2014 as Director of Education of the Christiane-Kühne Center for Allergy Research and Education (CK-CARE).

Research Advancement (Forschungsförderung)
■ Dr med. Simone Goldinger received a research grant “Filling the Gap”, a research advancement program funded by the University of Zurich until end of 2015
■ Dr med. Emmanuella Guenova-Hötzenecer received by the SNF a highly competitive career advancement of the Marie Heim-Vögtlin foundation for research in tumor immunology and cutaneous lymphoma
■ PD Dr med. Wolfram Hötzenecer received advancement funds of the innovation pool of the University Hospital of Zurich for the establishment of lymphocyte transformation tests at the department of allergy in our clinic
Our continuous efforts in medical education, public relations, marketing, and networking with private practitioners is only possible thanks to external funding. We collaborate with industry for our postgraduate education, giving private practitioners and industry a platform for communication and exchange. Furthermore possibilities are provided by our charitable foundations the Bruno Bloch Stiftung and the Verein für Hautkrebsforschung. We would here like to acknowledge with great respect the support of our industrial partners. Their collaboration supports the quality and nature of our postgraduate teaching offer. The Department of Dermatology USZ is grateful to the following sponsors and donators for their constant precious and generous support.

With special acknowledgement to our partners of “Schwerpunkt Hautkrebs”

Avène/Pierre Fabre
Cosmétique Active, Schweiz AG
(La Roche-Posay, Laboratoires Vichy)
Galderma SA
Roche Pharma (Schweiz) AG

“Schwerpunkt Entzündliche Hautkrankheiten”

AbbVie AG
Amgen Switzerland AG
Celgene GmbH
Janssen-Cilag AG
Merck Sharp & Dohme AG
Pfizer AG

Further Corporate Supporters

Actelion (Schweiz) AG
ALK Abello
Allergomed AG
Allmiral AG
Astellas Pharma AG
AstraZeneca AG
Bauerfeind AG
Bayer (Schweiz) AG
Biotest AG
Bristol-Myers Squibb AG
Coloplast AG
CSL Behring (Schweiz) AG
 Dermapharm AG
Drossa Pharm AG
Ganzoni & Cie AG
Gebro Pharma AG
Geistlich Pharma AG
Glaxo Smith Kline AG
J-P, F & E Hottinger & Co, Effektenhändler
IBSA Institut Biochimique SA
Johnson & Johnson Medical
Meda Pharma GmbH
Mundipharma Medical Company SA
Novartis (Schweiz) AG
Permamed AG
Qualicare AG
Roche Pharma (Schweiz) AG
Servier (Suisse) SA
Smith & Nephew AG
Trimedal AG
Waldmann Lichttechnik GmbH
Valucept
Charitable foundations closely associated with the Department of Dermatology USZ

Bruno Bloch Stiftung
Secretariat:
Dermatologische Klinik, Direktion
UniversitätsSpital Zurich
Gloriastrasse 31
8091 Zurich
brunoblochstiftung@usz.ch

Bank details:
UBS AG
8091 Zurich
Bank account No. 206-P0238697.0
Keyword “BrunoBlochStiftung”
IBAN: CH 59 0020 6206 P023 8697 0
SWIFT: UBSWCHZH80A
Clearing-No.: 298

Verein für Hautkrebsforschung
Secretariat:
Dermatologische Klinik
UniversitätsSpital Zurich
Gloriastrasse 31
8091 Zurich
info@skincancer.ch, www.skincancer.ch

Bank details:
Jean-Philippe, François & Emmanuel Hottinger & Co.,
Effektenhändler, Zurich

Bank: Credit Suisse Zurich
Swift: CRESCHZZ80A
Clearing-No.: 4835
Beneficiary: Verein für Hautkrebsforschung
Account CHF: IBAN: CH80 0483 5076 6289 5100 0
Reference: ALO 426
<table>
<thead>
<tr>
<th>Name</th>
<th>Title/Institution</th>
<th>Topic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anliker</td>
<td>MD Department of Dermato-Allergology, University</td>
<td>Clinical Pearls</td>
</tr>
<tr>
<td></td>
<td>Hospital St. Gallen, CH</td>
<td></td>
</tr>
<tr>
<td>Argenziano</td>
<td>Prof. Department of Dermatology, Second University</td>
<td>Spitz/Reed Nev (Dermatoscopy Course),</td>
</tr>
<tr>
<td></td>
<td>Hospital Naples, IT</td>
<td>Clues not to miss melanoma</td>
</tr>
<tr>
<td>Ballmer</td>
<td>MD Paul Scherer Institute CH</td>
<td>Structural and functional analysis of VEGF</td>
</tr>
<tr>
<td></td>
<td></td>
<td>signaling in angiogenesis: or how basic research led to the</td>
</tr>
<tr>
<td></td>
<td></td>
<td>discovery of new, highly specific</td>
</tr>
<tr>
<td></td>
<td></td>
<td>receptor-inhibitory molecules</td>
</tr>
<tr>
<td>Banholzer</td>
<td>MD Private Praxis, Zurich, CH</td>
<td>Jahresthema II: Hautanhangserkrankungen - Haartransplantationen -</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Indikationen, Ergebnisse, Grenzen</td>
</tr>
<tr>
<td>Bernauer</td>
<td>Prof. Ophthalmologist, Private Praxis, Zurich, CH</td>
<td>Entzündungen am und um das Auge</td>
</tr>
<tr>
<td>Beck</td>
<td>MD Private Praxis, Zurich, CH</td>
<td>Kutane Leishmaniose - Diagnostik und Therapie</td>
</tr>
<tr>
<td>Betschart</td>
<td>Cornelia MD Gynäkologie, UniversitätsSpital Zürich,</td>
<td>Erkrankungen des weiblichen Genitales</td>
</tr>
<tr>
<td></td>
<td>CH</td>
<td></td>
</tr>
<tr>
<td>Bezzola</td>
<td>Alain MD Private Praxis, Geneva, CH</td>
<td>Blepharoplastik</td>
</tr>
<tr>
<td>Bircher</td>
<td>Andreas Prof. Dept of Allergology, University Hospital</td>
<td>Fusculus Furious - Mollia Supra Magister</td>
</tr>
<tr>
<td></td>
<td>Basel, CH</td>
<td></td>
</tr>
<tr>
<td>Blum</td>
<td>Prof. Private practice, Konstanz, DE</td>
<td>Recurrent Nvi and Mucosal Lesions</td>
</tr>
<tr>
<td></td>
<td></td>
<td>(Dermatoscopy Course)</td>
</tr>
<tr>
<td>Boehmcke</td>
<td>Wolf-Henning Prof. Head Department of Dermatology, HUG</td>
<td>What's new in Psoriasis?</td>
</tr>
<tr>
<td></td>
<td>Geneva, CH</td>
<td></td>
</tr>
<tr>
<td>Borelli</td>
<td>Siegfried MD Dept of Dermatology, Stadtpital Triemil</td>
<td>Regionale Dermatosen: Intertrigo Erkrankungen</td>
</tr>
<tr>
<td></td>
<td>Zurich, CH</td>
<td></td>
</tr>
<tr>
<td>Bruckner-Tuderman</td>
<td>Leena Prof. Universitäts-Hautklinik Freiburg, DE</td>
<td>Von hereditären Epidermosen zu Hautfragilitätssyndrom - Ursachen,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mechanismen und Therapien</td>
</tr>
<tr>
<td>Brueggen</td>
<td>Charlotte MD Dermatology, Medical University of</td>
<td>Diverse T cell responses lead to the different manifestations of</td>
</tr>
<tr>
<td></td>
<td>Vienna, AT</td>
<td>cutaneous graft-versus-host disease</td>
</tr>
<tr>
<td>Burg</td>
<td>Günther Prof. Zurich, CH (retired)</td>
<td>Vita Prof. Dr Dr h.c. Urs Walter Schryder</td>
</tr>
<tr>
<td>Chaloupka</td>
<td>Karla MD Dept of Ophthalmology, University Hospital</td>
<td>Chirurgie: Onkologische Augenlidchirurgie und Orbitalchirurgie</td>
</tr>
<tr>
<td></td>
<td>Zurich, CH</td>
<td></td>
</tr>
<tr>
<td>della Torre</td>
<td>Rocco MD Dept of Dermatology, Inselspital Bern, CH</td>
<td>Mohs' mikrographische Chirurgie: Abschluss, Procedere</td>
</tr>
<tr>
<td>de Viragh</td>
<td>Pierre MD Private Praxis, Zurich, CH</td>
<td>Jahresthema II: Hautanhangserkrankungen – Management von Haarproblemen</td>
</tr>
<tr>
<td></td>
<td></td>
<td>in der Praxis</td>
</tr>
<tr>
<td>Elsaesser</td>
<td>Peter Prof. Dept of Dermatology and Allergology,</td>
<td>Duftstoffallergien in Europa</td>
</tr>
<tr>
<td></td>
<td>University Hospital Jena, DE</td>
<td></td>
</tr>
<tr>
<td>Engel</td>
<td>Peter MD Klinik für Kinder und Jugendliche, Kantonss</td>
<td>Immunotherapie: von Blamoutier bis heute</td>
</tr>
<tr>
<td></td>
<td>spital Aarau, Aarau, CH</td>
<td></td>
</tr>
<tr>
<td>Gaide</td>
<td>Olivier MD Department of Dermatology, CHU/Lausanne,</td>
<td>Quiz Fällle (Dermatoscopy Course)</td>
</tr>
<tr>
<td></td>
<td>CH</td>
<td></td>
</tr>
<tr>
<td>Göschke</td>
<td>Benedikt MD Specialist for Skin Diseases, Bern, CH</td>
<td>Regionale Dermatosen: Erkrankungen bei dunkler Haut</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Guggenheim</td>
<td>Merlin PD Klinik für Plastische Chirurgie und Handchirurg,</td>
<td>Chirurgische Melanombehandlung</td>
</tr>
<tr>
<td></td>
<td>UniversitätsSpital Zürich, CH</td>
<td></td>
</tr>
<tr>
<td>Haneke</td>
<td>Eckart Prof. Dept of Dermatology, Inselspital Bern,</td>
<td>Jahresthema II: Hautanhangserkrankungen – Chirurgie des Nagelappаратs</td>
</tr>
<tr>
<td></td>
<td>CH</td>
<td></td>
</tr>
<tr>
<td>Häusermann</td>
<td>Peter PD Dept of Dermatology, University Hospital,</td>
<td>Therapie der harrnäckigen Rosazea und POD</td>
</tr>
<tr>
<td></td>
<td>Basel, CH</td>
<td></td>
</tr>
<tr>
<td>Hausmann</td>
<td>Oliver MD Löwenpraxis, Luzern, CH</td>
<td>Allergien und Intoleranzen auf Biologicals</td>
</tr>
<tr>
<td>Hertl</td>
<td>Michael Prof. Universitätsklinikum Giessen und Marburg,</td>
<td>Entzündliche Dermatosen: Pemphigoiderkrankungen</td>
</tr>
<tr>
<td></td>
<td>Marburg, DE</td>
<td></td>
</tr>
<tr>
<td>Hess</td>
<td>Monika MD Private Praxis, Zurich, CH</td>
<td>Mohs' mikrographische Chirurgie/Nagelchirurgie</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ittin</td>
<td>Peter Prof. Dept of Dermatology, University Hospital</td>
<td>Jahresthema I: Hautanhangserkrankungen – Ektodermale Dysplasien</td>
</tr>
<tr>
<td></td>
<td>Basel, CH</td>
<td></td>
</tr>
<tr>
<td>Jemec</td>
<td>Gregor Prof. Department of Dermatology, Roskilde</td>
<td>Jahresthema Teil I: Hautanhangserkrankungen – Pathogenese und</td>
</tr>
<tr>
<td></td>
<td>Hospital, Roskilde, DK</td>
<td>medikamentöse Therapie der Acne inversa</td>
</tr>
<tr>
<td>Kágler</td>
<td>Martin MD Private Praxis, Zurich, CH</td>
<td>Fillertherapie in der Praxis</td>
</tr>
<tr>
<td>Kazakov</td>
<td>Dmitry Prof. Ski's Department of Pathology, Charles</td>
<td>Jahresthema Teil I: Hautanhangserkrankungen - Axinatumoren - benign</td>
</tr>
<tr>
<td></td>
<td>University, Medical Faculty Hospital Pilsen, CZ</td>
<td>or malignant? - Tumorsyndrome</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Position/Institution</td>
<td>Topic</td>
</tr>
<tr>
<td>--------------------</td>
<td>--------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>Krasovec Marguerite</td>
<td>MD Private Praxis, Schlieren, CH</td>
<td>Lineare IgA Dermatose, IgM-Dermatose</td>
</tr>
<tr>
<td>Lautenschlager</td>
<td>Stephan Prof. Dermatol. Ambulatorium, Stadtspital Triemli, Zurich, CH</td>
<td>Jahresthema II: Hautanhangserkrankungen - Tumoren des Nagelapparates - Nagelchirurgie</td>
</tr>
<tr>
<td>Levine John</td>
<td>Prof. Pediatric Hematology &amp; Oncology, C.S. Mott Children’s Hospital Michigan, USA</td>
<td>The role of photopheresis in the pre-emptive treatment of GVHD</td>
</tr>
<tr>
<td>Lutz Franz</td>
<td>MD CHUV Lausanne, CH</td>
<td>Arenaviruses: from lethal immune pathology to a vaccine</td>
</tr>
<tr>
<td>Marghoob Ash</td>
<td>Prof. Memorial Sloan Kettering Cancer Center, New York, USA</td>
<td>2 step algorithm (Dermatoscopy Course) / Non melanocytic lesions</td>
</tr>
<tr>
<td>Martin Roland</td>
<td>Prof. Neurology, University Hospital Zurich, CH</td>
<td>Characteriza</td>
</tr>
<tr>
<td>Michielin Olivier</td>
<td>Prof. Professor at the Medical Faculty, University of Lausanne, SIB Molecular Modelling Group, Lausanne, CH</td>
<td>Update Immunotherapy: Ipilimumab &amp; PD</td>
</tr>
<tr>
<td>Mühlstädt Michael</td>
<td>MD Klinik u. Poliklinik für Dermatologie und Allergologie, München, DE</td>
<td>Elektrochemotherapie - Mohs' mikrographische Chirurgie: Nachexzisionen / Rekonstruktionen</td>
</tr>
<tr>
<td>Müller Andre-as-Paul</td>
<td>MD Gastrozentrum Klinik Hirslanden Zürich, CH</td>
<td>Pruritus ani - diagnostische und therapeutische Aspekte</td>
</tr>
<tr>
<td>Navarini Alexander</td>
<td>PD King’s College London, GB</td>
<td>Exom sequencing in the Dermatology</td>
</tr>
<tr>
<td>Nenoff Pietro</td>
<td>Prof. Facharzt für Haut- und Geschlechtskrankheiten, Möllis, DE</td>
<td>Pilzkrankungen: Diagnostik und Therapie</td>
</tr>
<tr>
<td>Oberholzer Patrick</td>
<td>PD Dept of Dermatology, Inselspital Bern, CH</td>
<td>Neue therapeutische Ansätze bei Basalzellaninzonen</td>
</tr>
<tr>
<td>Pachlönk Jana</td>
<td>MD Children’s Hospital Zurich, CH</td>
<td>Biologicals for Haemophagocytic Syndromes</td>
</tr>
<tr>
<td>Philipp-Dormston</td>
<td>Wolfgang MD Hautzentrum Köln, Köln, DE</td>
<td>Was’s Nev 1: Neuigkeiten in der ästhetischen Medizin</td>
</tr>
<tr>
<td>Pichler Werner</td>
<td>Prof. Head Dept of Allergology, Inselspital Bern, CH</td>
<td>Allergien &amp; Intoleranzen: Schwere Medikamenteneaktionen: Mechanismus und Genetik</td>
</tr>
<tr>
<td>Plaza Tobias</td>
<td>MD Center of Skin and Allergy, Uster, CH</td>
<td>Praxiszertifizierung: Praktische Tipps und Tricks</td>
</tr>
<tr>
<td>Röcken Martin</td>
<td>Prof. Leitung Hautklinik, Universitäts-Hautklinik Tübingen, DE</td>
<td>Psoriasis</td>
</tr>
<tr>
<td>Renz Harald</td>
<td>Prof. Institute of Laboratory Medicine and Pathobiology, Philipps University Marburg, DE</td>
<td>Nervensystem und Allergien</td>
</tr>
<tr>
<td>Röddorf Tamara</td>
<td>MD Klinik für Onkologie, Universitäts-Spital Zürich, CH</td>
<td>Organsspezifische Besonderheiten von lymphoproliferativen Erkrankungen</td>
</tr>
<tr>
<td>Rümmelein Bettina</td>
<td>MD Fachätztin für Dermatologie, Seepital Kilchberg, CH</td>
<td>Workshop: Botox</td>
</tr>
<tr>
<td>Ruzicka Thomas</td>
<td>Prof. Leitung Klinik und Poliklinik für Dermatologie und Allergologie TU München, DE</td>
<td>Bruno Bloch-Gedächtnissvorlesung: Akne</td>
</tr>
<tr>
<td>Schaller Martin</td>
<td>Prof. Universitäts-Hautklinik Tübingen, DE</td>
<td>Jahresthema Teil I: Hautanhangserkrankungen - Neuigkeiten zur Akne</td>
</tr>
<tr>
<td>Schwarz Thomas</td>
<td>Prof. Klinik für Dermatologie, Allergologie u. Venerologie, Univ.Klinikum Schleswig-Holstein, Kiel, Deutschland</td>
<td>Wirkungsmechanismus der ECP</td>
</tr>
<tr>
<td>Skaria André</td>
<td>MD Specialist of Dermatology Lausanne/Vevey, CH</td>
<td>Was’s Nev 2: Chirurgie</td>
</tr>
<tr>
<td>Steiger Marco</td>
<td>MD Oberarzt Dermatologie, Inselspital Bern</td>
<td>Mohs’ mikrographische Chirurgie: Nachexzisionen / Rekonstruktionen</td>
</tr>
<tr>
<td>Stuart Darrin</td>
<td>MD Novartis Schweiz, CH</td>
<td>Modelling vemurafen resistance in melanoma reveals a strategy to forestall drug resistance</td>
</tr>
<tr>
<td>Surace Laura</td>
<td>MD Oncology, University Hospital Zurich, CH</td>
<td>Immune-response related pathways activated by radiotherapy and their impact on therapeutic efficacy</td>
</tr>
<tr>
<td>Thomas Luc</td>
<td>Prof. Department of Dermatology, Hospital of Dieu, Lyon, FR</td>
<td>Lesions of the face (Dermatoscopy Course) / Dysplastic nevi / Digital dermoscopy follow up</td>
</tr>
<tr>
<td>van den Broek Maries</td>
<td>Prof. Oncology, University Hospital Zurich, CH</td>
<td>Aldara is more than Imiquimod</td>
</tr>
<tr>
<td>Volz Andreas</td>
<td>MD Dermatologie, Universitätsspital Basel, CH</td>
<td>Mohs’ mikrographische Chirurgie/Nagelchirurgie - Mohs’ mikrographische Chirurgie: Nachexzisionen / Rekonstruktionen</td>
</tr>
<tr>
<td>Wüthrich Brunello</td>
<td>Prof. Zurich, CH (retired)</td>
<td>45 Jahre Nahrungsmittelallergien - ein Rückblick</td>
</tr>
<tr>
<td>Zalaudek Iris</td>
<td>Prof. Department of Dermatology, University Hospital Graz, A</td>
<td>Benign Melanocytic lesions (Dermatoscopy Course) / Demoscopy in general dermatology</td>
</tr>
<tr>
<td>Zillikens Detlef</td>
<td>Prof. Universitätsklinikum Schleswig-Holstein, Lübeck, DE</td>
<td>Entzündliche Dermatosen: Pemphiguskerkrankungen</td>
</tr>
</tbody>
</table>
15. Publications

Publications 2013

Original papers (peer-reviewed)

Accart, Nathalie; Urosevic-Maiwald, Mirjana; Dummer, Reinhard; Bataille, Vincent; Kehrer, Nadine; Niculescu, Cristina; Limacher, Jean-Marc; Chenard, Marie-Pierre; Bonnefoy, Jean-Yves; Rooke, Ronald. Lymphocytic infiltration in the cutaneous lymphoma microenvironment after injection of TG1042. Journal of Translational Medicine 2013; 11: 226

Argenziano, Giuseppe; Giacomel, Jason; Zalaudek, Iris; Blum, Andreas; Braun, Ralph P; Cabo, Horacio; Halpern, Allan; Hofmann-Wellenhof, Rainer; Malvehy, Josep; Marghoob, Ashfaq A; Menzies, Scott; Moscarella, Elvira; Pellacani, Giovanni; Puig, Susana; Rabínovitz, Harold; Said, Toshiaki; Seidenari, Stefania; Soyer, H Peter; Stolz, Wilhelm; Thomas, Luc: Ketterl, Harald. A clinico-dermoscopic approach for skin cancer screening: recommendations involving a survey of the International Dermoscopy Society. Dermatologic Clinics 2013; 31: 525-534, vii

Ascierto, Paolo A; Schadendorf, Dirk; Berking, Cora; Agarwala, Sanjiv S; van Herpen, Carla Ml; Queirolo, Paola; Blank, Christian U; Hauschild, Axel; Beck, J Thaddeus; St-Pierre, Annie; Niazi, Faiz; Wandel, Simon; Peters, Malte; Zubel, Angela; Dummer, Reinhard. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncology 2013; 14: 249-256

Assaf, Chalid; Becker, Jürgen C; Beyer, Marc; Cozzio, Antonio; Dippel, Edgar; Klemke, Claus-Detlev; Kurschat, Peter; Weichenhal, Michael; Studer, Rudolf. Treatment of advanced cutaneous T-cell lymphomas with non-pegylated liposomal doxorubicin--consensus of the lymphoma group of the Working Group Dermatologic Oncology. JDDG - Journal der Deutschen Dermatologischen Gesellschaft 2013; 11: 338-347

Badertscher, N; Braun, R P; Held, U; Kofmehl, R; Senn, O; Hofbauer, G F; Rossi, P O; Wensing, M J; Hoetzenecker, W; Guenova-Hötzenecker, E; Meisner, C; Maetzke, J; Schaefer, T; Eberlein, B; Scharffetter-Kochanek, K; Rocken, M. Efficacy of bath psoralen plus ultraviolet A (PUVA) vs. system PUVA in psoriasis: a prospective, open, randomized, multicentre study. British Journal of Dermatology 2013; 169: 704-708

Bekou, V; Baltisser, I; Dummer, R; Traber, J. Ulkus planar bei multimorbiden Patienten. Der Chirurg 2013; 84: 222-224

Belloni, Benedetta; Lamberti, Chiara; Nuñez, Paolo; Philips, Jay; Bruening, Eric; Wong, Stephanie; Dummer, Reinhard. Will PAXgene substitute formalin? A morphological and molecular comparative study using a new fixative system. Journal of Clinical Pathology 2013; 66: 124-135

Bernerburg, M; Herzinger, T; Rampf, J; Hoetzenecker, W; Guenova-Hötzenecker, E; Meisner, C; Maetzke, J; Schaefer, T; Eberlein, B; Scharffetter-Kochanek, K; Rocken, M. Efficacy of bath psoralen plus ultraviolet A (PUVA) vs. system PUVA in psoriasis: a prospective, open, randomized, multicentre study. British Journal of Dermatology 2013; 169: 704-708
Bosshard, Philipp P. Usefulness of IgM-specific enzyme immunoassays for serodiagnosis of syphilis: comparative evaluation of three different assays. Journal of Infection 2013; 67: 35-42

Bouchaud, Grégory; Gehrke, Samuel; Krieg, Carsten; Kolios, Antonios; Hafner, Jürg; Navarini, Alexander A; French, Lars E; Boyman, Onur. Epidermal IL-15Ralph acts as an endogenous antagonist of psoriasis inflammation in mouse and man. Journal of Experimental Medicine 2013; 210: 2105-2117

Braun, Ralph P; Thomas, L; Dusza, S W; Gaide, O; Menzies, S; Dalle, S; Blum, A; Argenziano, G; Zalaudek, I; Kopf, A; Rabinovitz, H; Oliviero, M; Perrinaud, A; Cabo, H; Pizzichetta, M; Pozo, L; Langford, D; Tanaka, M; Saida, T; Perusquia Ortiz, A M; Kreusch, J; De Giorgi, V; Piccolo, D; Grichnik, J M; Kitterl, H; Puig, S; Malvehy, J; Seidenari, S; Stanganelli, I; French, L; Marghoob, A A. Dermatoscopy of acral melanoma: a multicenter study on behalf of the international dermoscopy society. Dermatology 2013; 227: 373-380

Cippà, Pietro E; Kamarashev, Jivko; Chen, Jin; Kraus, Anna K; Segerer, Stephan; Feldmeyer, Laurence; Fehr, Thomas. Synergistic Bcl-2 inhibition by ABT-737 and cyclosporine A. Apoptosis 2013; 18: 315-323


Cozzio, A; French, L E. Genodermatoses. Der Hautarzt 2013; 64: 5-6

Cronin, Julie C; Watkins-Chow, Dawn E; Incio, Art; Hasskamp, Joanne H; Schönewolf, Nicola; Aude, Lauren G; Hayward, Nicholas K; Bastian, Boris C; Dummer, Reinhard; Loftus, Stacie K; Pavan, William J. SOX10 ablation arrests cell cycle, induces senescence, and suppresses melanomagenesis. Cancer Research 2013; 73: 5079-5078

Dalton, Lucy E; Kamarashev, Jivko; Barinaga-Rementeria Ramirez, Irene; White, Gavin; Malliri, Angeliki; Hurstone, Adam. Constitutive RAC activation is not sufficient to initiate melanocyte neoplasia but accelerates malignant progression. Journal of Investigative Dermatology 2013; 133: 1572-1581

Das Thakur, Meghna; Salangsang, Fernando; Landman, Allison S; Sellers, William R; Pryer, Nancy K; Levesque, Mitchell P; Dummer, Reinhard; McMahon, Martin; Stuart, Darrin D. Modeling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013; 494: 251-255

de Respirin, Sophie; Tonolla, Mauro; Pranghofer, Sigrid; Petrini, Liliane; Petrini, Orlando; Bosshard, Philipp P. Identification of dermatophytes by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Medical Mycology 2013; 51: 514-521

DeSimone, Jennifer A; Guenova-Hötzeckecker, Emmanuella; Carter, Joi B; Chaney, Keri S; Aldridge, Julie R; Noel, Claire M; Dorosario, Andrew A; Hansen, Jorgen I; Kupper, Thomas S; Devlin, Phillip M. Low-dose high-dose-rate brachytherapy in the treatment of facial lesions of cutaneous T-cell lymphoma. Journal of the American Academy of Dermatology 2013; 69: 61-65

Döbbeling, Udo; Waeckerle-Men, Ying; Zabel, Franziska; Graf, Nicole; Kündig, Thomas M; Johansen, Pål. The antihistamines clemastine and desloratadine inhibit STAT3 and c-Myc activities and induce apoptosis in cutaneous T-cell lymphoma cell lines. Experimental Dermatology 2013; 22: 119-124

Dummer, R; Mangana, J. Carboplatin, paclitaxel and sorafenib in advanced melanoma - what have we learned?. Translational Cancer Research 2013; 2: 46-47

Duivic, Madeleine; Dummer, Reinhard; Becker, Jürgen C; Poulalhon, Nicolas; Ortiz Romero, Pablo; Grazia Bernengo, Maria; Lebbé, Celeste; Assaf, Chalid; Squier, Margaret; Williams, Denise; Marshod, Miriam; Tai, Feng; Prince, H Miles. Panobinostat activity in both bexarotene-exposed and -naïve patients with refractory cutaneous T-cell lymphoma: Results of a phase II trial. European Journal of Cancer 2013; 49: 386-394

Feldmeyer, Laurence; Shojaati, Golnar; Spanaas, Katharina-Susanne; Navarini, Alexander; Theiler, Barbara; Donghi, Davide; Urosevic-Maiwald, Mirjana; Glatz, Martin; Imhof, Laurence; Barysch, Marjam J; Dummer, Reinhard; Roos, Magorzata; French, Lars E; Surber, Christian; Hofbauer, Günther F L. Phototherapy with UVB narrowband, UVA/UVBnb, and UVA1 differentially impacts serum 25-hydroxyvitamin-D3. Journal of the American Academy of Dermatology 2013; 69: 530-536

Geier, J; Lessmann, H; Skudlik, C; Ballmer-Weber, B K; Weisshaar, E; Uter, W; Schnuch, A. Berufsbedingte Kontaktallergie bei Maurern, Fliesenlegern und Angehörigen verwandter Berufe. Allergologie 2013; 36: 252-266

Geier, Johannes; Ballmer-Weber, Barbara K; Dickel, Heinrich; Frosch, Peter J; Bircher, Andreas; Weisshaar, Elke; Hillen, Uwe. Monitoring contact sensitization to p-phenylenediamine (PPD) by patch testing with PPD 0.3% in petrolatum. Contact Dermatitis 2013; 69: 25-31

Glatz, M; Achermann, Y; Kerl, K; Bosshard, P P; Cozzio, A. Nodular secondary syphilis in a woman. BMJ Case Reports 2013; 2013: 1-5

Glatz, M; Schmid-Grendelmeier, P. Bettle Dermatitis. Imported Skin Disease 2013; 273-282

Guenova-Hötzeckecker, Emmanuella; Hötzeckecker, Wolfram; Kisue, Geoffrey; Teske, Anna; Heeg, Peter; Voykov, Bogomil; Hötzeckecker, Konrad; Schippert, Wilfried; Moehrl, Matthäus. Banana leaves as an alternative wound dressing. Dermatologic Surgery 2013; 39: 290-297
Guerrero-Hötzenecker, Emmanuella; Watanabe, Rei; Teague, Jessica E; Desimone, Jennifer A; Jiang, Ying; Dowlatshahi, Mitra; Schlabach, Christina; Schaeckel, Knut; Rook, Alain H; Tawa, Marianne; Fisher, David C; Kupper, Thomas S; Clark, Rachael A. TH2 cytokines from malignant cells suppress TH1 responses and enforce a global TH2 bias in leukemic cutaneous T-cell lymphoma. Clinical Cancer Research 2013; 19: 3755-3763

Hafner, J; Geiges, M L; Burg, G; French, L E. Zürich stellt sich vor: Eine beachtliche Geschichte - ein beachtlicher Leistungs- ausweis. Dermatologie Praxis 2013; 20-22

Hoetzenecker, K; Mitterbauer, A; Guerrero-Hötzenecker, Emanuell; Schweiger, U; Allmann, P; Zimmermann, M; Hofbauer, H; Beer, L; Klepetko, W; Ankersmit, H J. High levels of lung resident CD4+CD28null cells in COPD: implications of autoimmunity. Wiener klinische Wochenschrift 2013; 125: 150-155


Hoetzenecker, Wolfram; Guerrero-Hötzenecker, Emmanuella; Mitte, Vanyo; Schanz, Stefan; Ulmer, Anja; Fierlbeck, Gerhard. Treatment of pyoderma gangrenosum with topical factor XIII. European Journal of Dermatology 2013; 23: 653-657

Hompes, S; Grünhagen, J; Schmid-Grendelmeier, P; Michel, S; Worm, M. Seltene Nahrungsmittelallergene - Daten aus dem Anaphylaxie-Register. Allergologie 2013; 36: 204-209

Iolyeva, Maria; Aebischer, David; Proulx, Steven T; Willrodt, Ann-Helen; Eccleifer, Tatiana; Härer, Simone; Bouchaud, Grégory; Krieg, Carsten; Onder, Lucas; Ludewig, Burkhard; Santambrogio, Laura; Boymann, Onur; Gulyészki, Gabor; Becher, Burkhard; Weder, Walter; Münz, Christian. Cytokine complex-expanded natural killer cells improve allogeneic lung transplant function via depletion of donor dendritic cells. American Journal of Respiratory and Critical Care Medicine 2013; 187: 1349-1359

Kaiser, Dominik; Hafner, Jürg; Mayer, Dieter; French, Lars E; Läuclhi, Severin. Alginate dressing and polyurethane film versus paraffin gauze in the treatment of split-thickness skin graft donor sites: a randomized controlled pilot study. Advanc es in Skin & Wound Care 2013; 26: 67-73


Jankovic, Dragana; Ganesan, Jayanthi; Bechaider, Michael; Stickel, Natalie; Weber, Felix C; Guarda, Greta; Follo, Marie; Pfeifer, Dietmar; Tardivel, Aubry; Ludigs, Kristina; Bouazzouli, Abdelatif; Keri, Katrin; Fischer, Julius C; Haas, Tobias; Schmitt-Gräfl, Annette; Manoharan, Anand; Müller, Leonard; Finke, Jürgen; Martin, Stefan F; Gorka, Oliver; Peschel, Christian; Ruland, Jürgen; Idzko, Marco; Duyster, Justus; Holler, Ernst; French, Lars E; Poeck, Hendrik; Contassot, Emmanuel; Zeiser, Robert. The Nlrp3 inflammasome regulates acute graft-versus-host disease. Journal of Experimental Medicine 2013; 210: 1899-1910


Jungfrau, Wolfgang; Codarri, Laura; Bouchaud, Gregory; Krieg, Carsten; Boymann, Onur; Gulyészki, Gabor; Becher, Burkhard; Weder, Walter; Münz, Christian. Cytokine complex-expanded natural killer cells improve allogeneic lung transplant function via depletion of donor dendritic cells. American Journal of Respiratory and Critical Care Medicine 2013; 187: 1349-1359

Kaiser, Dominik; Hafner, Jürg; Mayer, Dieter; French, Lars E; Läuclhi, Severin. Alginate dressing and polyurethane film versus paraffin gauze in the treatment of split-thickness skin graft donor sites: a randomized controlled pilot study. Advances in Skin & Wound Care 2013; 26: 67-73


Kempf, Werner; Kazakov, Dmitry V; Cozzio, Antonio; Kamareshev, Jivko; Keri, Katrin; Plaza, Tobias; Metze, Dieter. Primary cutaneous CD8+ small- to medium-sized Lymphoproliferative disorder in extrafacial sites: Clinopathologic features and concept on their classification. American Journal of Dermatopathology 2013; 35: 159-166


Kempf, Werner; Kazakov, Dmitry V; Schärer, Leo; Rütten, Arno; Mentzel, Thomas; Paredes, Bruno E; Palmedo, Gabriele; Pani zincon, Renato G; Kutzner, Heinz. Angioinvasive Lymphomato id

Kerl, Katrin; Leo, Schärer; Hesse, Raphael; Hesse, Benedikt; Gabriela, Palmedo; Requena, Luis; Wiesner, Thomas; Kutzner, Heinz. Two-dimensional visualization of multicolor FISH-generated data as a helpful tool for the analysis and understanding of cytogenetic and chromosomal alterations in melanocytic lesions. American Journal of Dermatopathology 2013; 35: 151-158

Klimek, L; Willers, J; Schendzielorz, P; Kündig, T M; Senti, G. Immunotherapy of the allergic rhinitis without Allergene?: Neue Möglichkeiten einer Immunmodulation durch Vakzinerung mittels „virus-like particles“ und CpG-Motiven. HNO 2013; 61: 826-833

Kolios, Antonios G A; Marques Maggio, Ewerton; Guibert, Christoph; Cozzio, Antonio; Dummer, Reinhard; French, Lars E; Navarini, Alexander A. Oral, esophageal and cutaneous lichen ruber planus controlled with alitretinoin: case report and review of the literature. Dermatology 2013; 226: 302-310

Kolm, I; Pawlik, E; Eggmann, N; Kamarachev, J; Kerl, K; French, L E; Hofbauer, G F L. Subacute cutaneous lupus erythematosus triggered by radiotherapy. Case Reports in Dermatology 2013; 5: 232-235

Konstantinou, G N; Asero, R; Ferrer, M; Kolios, C; Maurer, M; Raap, U; Schmid-Grendelmeier, P; Skol, P S; Grattan, C E H. EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria. Allergy 2013; 68: 27-36

Läuchli, S; Bayard, I; Hafner, J; Hunziker, T; Mayer, D; French, L. Unterschiedliche Abheilungsdauer und Häufigkeit der Läuchli, S; Bayard, I; Hafner, J; Hunziker, T; Mayer, D; French, L. Unterschiedliche Abheilungsdauer und Häufigkeit der

Le, Thuy-My; Bublin, Merima; Breiteneder, Heimo; Fernández-Rivas, Montserrat; Asero, Riccardo; Ballmer-Weber, Barbara; Barreales, Laura; Bures, Peter; Belohlavkova, Simona; de Blay, Frédéric; Clausen, Michael; Dubakiene, Ruta; Gislaison, David; van Hoven, Els; Jedrzejczak-Czechowicz, Monika; Kowalski, Marek L; Kralimarkova, Tanya; Lidholm, Jonas; Dewitt, Asa Marknell; Mills, Clare E N; Papadopoulos, Nikolaos G; Popov, Todor; Purohit, Ashok; van Ree, Ronald; Seneviratne, Suranjith; Sinaniotis, Athanasios; Summers, Colin; Vázquez-Cortés, Sonia; Vieths, Stefan; Vogel, Lothar; Hoffmann-Sommergruber, Karin; Knulst, André C. Kiwifruit allergy across Europe: Clinical manifestation and IgE recognition patterns to kiwifruit allergens. Journal of Allergy and Clinical Immunology 2013; 131: 164-171

Lefort, Karine; Brooks, Yang; Ostano, Paola; Cario-André, Muriel; Calpini, Valérie; Guinea-Viniegra, Juan; Albinger-Hegyi, Andrea; Hoetzenecker, Wolfram; Kolfschoten, Ingrid; Wagner, Erwin F; Werner, Sabine; Dotto, Gian Paolo. A mir-34a-SIRT6 axis in the squamous cell differentiation network. EMBO Journal Online 2013; 32: 2248-2263

Menzies, Scott W; Moloney, Fergal J; Byth, Karen; Avramidis, Michelle; Argenziano, Giuseppe; Zalaudek, Iris; Braun, Ralph P; Malvehy, Joseph; Puig, Susana; Rabinovitz, Harold S; Oliviero, Margaret; Cabo, Horacio; Bono, Riccardo; Pizzichetta, Maria A; Claeson, Magdalena; Gaffney, Daniel C; Soyer, H Peter; Stanganelli, Ignazio; Scolyer, Richard A; Gafar, Pascale; Kelly, John; McCurdy, Olivia; Llambrich, Alex; Marghoob, Ashfaq A; Zaballo, Pedro; Kirchsch, Herbert M; Piccolo, Domenico; Bowling, Jonathan; Thomas, Luc; Terstappen, Karin; Tanaka, Masaru; Pellacani, Giovanni; Pagnanelli, Gianluca; Ghiglotti, Giovanni; Ortega, Blanca Carlos; Crafter, Greg; Ortiz, Ana Maria Perusquia; Tromme, Isabelle; Kikasr, Isi Kilinc; Ozdemir, Fezal; Tam, Anthony; Landi, Christian; Norton, Peter; Kačar, Nida; Rudnicka, Lidia; Slowinska, Monika; Simionescu, Olga; Di Stefani, Alessandro; Coates, Elliot; Kreusch, Juergen. Dermoscopic evaluation of nodular melanoma. JAMA Dermatology 2013; 149: 699-709


Mitteldorf, C; Bieri, M; Wey, N; Kerl, K; Kamarachev, J; Pfaltz, M; Kutzner, H; Roncador, G; Tomasini, D; Kempf, W. Expression of PD-1 (CD279) in cutaneous B-cell lymphomas with correlation to lymphoma entities and biologic behavior. British Journal of Dermatology 2013; 169: 1212-1218

Mohanna, Mosab; Distler, Oliver; Sprott, Haiko; Kündig, Thomas; French, Lars E; Hofbauer, Günther. Skin lesions in anti-Pm-ScI-70 positive systemic sclerosis-dermatomyositis overlap syndrome improve during local PUVA phototherapy. European Journal of Dermatology 2013; 23: 730-731

Morand, G; Vital, D; Pézier, T; Holzmann, D; Roessle, M; Cozio, A; Huber, G F. Merkel cell carcinoma of the head and neck: a single institutional experience. Journal of Skin Cancer 2013; 325086

Mueheisen, Beda; Pazhenkottil, Aju; French, Lars E; Hofbauer, Günther F L. Nonmelanoma skin cancer in organ transplant recipients: increase without delay after transplant and subsequent acceleration. JAMA Dermatology 2013; 149: 618-620
Niesner, Heike; Forschner, Andrea; Klumpp, Bernhard; Honegger, Jürgen B; Witte, Maria; Bornemann, Antje; Dummer, Reinhard; Adam, Annemarie; Bauer, Jürgen; Tabatabai, Ghazal-eh; Flaherty, Keith; Sinnberg, Tobias; Beck, Daniela; Leiter, Ulrike; Mauch, Cornelia; Roesch, Alexander; Weide, Benjamin; Eigentler, Thomas; Schadendorf, Dirk; Garbe, Claus; Kulms, Dagmar; Quintanilla-Martinez, Leticia; Meier, Friedegund. Targeting hyperactivation of the Akt survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Medicine 2013; 2: 76-85

Nobbe, Stephan; Weibel, Lisa; Kuehne, Andreas; Gobbi, Sharon; Keri, Katrin; Cozzio, Antonio. PLEVA pemphigoides - synchronous features of PLEVA and bullous pemphigoid. JDDG - Journal der Deutschen Dermatologischen Gesellschaft 2011; 11: 445-447

Ogbah, Zighereda; Badenas, Celia; Harland, Mark; Puig-Butillé, Joan A; Elliot, Fay; Bonifaci, Nuria; Guino, Elisabet; Randerson-Moor, Julie; Chan, May; Iles, Mark M; Glass, Daniel; Brown, Andrew A; Carrera, Cristina; Kolm, Isabel; Bataille, Veronique; Spector, Timothy D; Malvéhy, Josep; Newton-Bishop, Julia; Pujana, Miquel A; Bishop, Tim; Puig, Susana. Evaluation of PAX3 genetic variants and nevus number. Pigment Cell & Melanoma Research 2013; 26: 666-676

Ogbah, Zighereda; Visa, Laura; Badenas, Celia; Rios, José; Puig-Butillé, Joan Anton; Bonifaci, Nuria; Guino, Elisabet; Augé, Josep Maria; Kolm, Isabel; Carrera, Cristina; Pujana, Miquel Angel; Malvéhy, Josep; Puig, Susana. Serum 25-hydroxyvitamin D3 levels and vitamin D receptor variants in melanoma patients from the Mediterranean area of Barcelona: 25-hydroxyvitamin D3 levels and VDR variants in melanoma patients from Barcelona. BMC Medical Genetics 2013; 14: 1-13

Panda, R; Ariyaratna, H; Amnuaycheewa, P; Tetteh, A; Pramod, S N; Taylor, S L; Ballmer-Weber, B K; Goodman, R E. Challenges in testing genetically modified crops for potential increases in endogenous allergen expression for safety. Allergy 2013; 68: 142-151

Pihlgren, Maria; Silva, Alberto B; Madani, Rime; Giriens, Valérie; Waeckerle-Men, Ying; Fettelschoss, Antonia; Hickman, David T; López-Deber, Maria Pilar; Ndao, Dorin Mlaki; Vukicevic, Marija; Buccarelio, Anna Lucia; Gafner, Valérie; Chuard, Nathalie; Reis, Pedro; Piorkowska, Kasia; Pfleifer, Andrea; Kündig, Thomas M; Muhs, Andreas; Johansen, Pål. TRIF- and TRIF-dependent stimulation of B lymphocytes by peptide liposomes enables T cell-independent isotype switch in mice. Blood 2013; 121: 85-94

Pizzichetta, Maria A; Talamini, Renato; Marghoob, Ash A; Snyder, H Peter; Argenziano, Giuseppe; Bono, Riccardo; Corradin, M Teresa; De Giorgi, Vincenzo; Gonzalez, Marian A; Kolm, Isabel; Kopf, Andrew W; Malvéhy, Joseph; Nami, Niccolò; Oliviero, Margaret; Pellacani, Giovanni; Puig, Susana; Rabinovitz, Harold; Rubegni, Pietro; Seidenari, Stefania; Stanganelli, Ignazio; Veronesi, Andrea; Zalaudek, Iris; Zampieri, Pierfrancesco; Menzies, Scott W. Negative pigment network: an additional dermoscopic feature for the diagnosis of melanoma. Journal of the American Academy of Dermatology 2013; 68: 552-559

Preussler, Stefan; Wenzel, Norman; Braun, Ralf-Peter; Owischimikow, Nina; Vogel, Carlo; Deninger, Anselm; Zadok, Avi; Woggon, Ulrike; Schneider, Thomas. Generation of ultra-narrow, stable and tunable millimeter- and terahertz- waves with very low phase noise. Optics Express 2013; 21: 23950-23962

Raaijmakers, Marieke I G; Rozati, Sima; Goldinger, Simone M; Widmer, Daniel S; Dummer, Reinhard; Levesque, Mitchell P. Melanoma immunotherapy: historical precedents, recent successes and future prospects. Immunotherapy 2013; 5: 169-182

Rinderknecht, Jeannine D; Goldinger, Simone M; Rozati, Sima; Kamarashev, Jivko; Keri, Katrin; French, Lars E; Dummer, Reinhard; Belloni, Benedetta. RASopathic skin eruptions during vemurafenib therapy. PLoS ONE 2013; 8: e58721

Robert, Caroline; Dummer, Reinhard; Gutzmier, Ralf; Lorigan, Paul; Kim, Kevin B; Nyakas, Marta; Arance, Ana; Lisskay, Gabriella; Schadendorf, Dirk; Cantarini, Mireille; Spencer, Stuart; Middleton, Mark R. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncology 2013; 14: 733-740

Rolf, Frank; Huber, Marcel; Gruber, Florian; Böhm, Friederike; Pfister, Herbert J; Bochkov, Valery N; Tschachler, Erwin; Dummer, Reinhard; Hohl, Daniel; Schäfer, Matthias; Werner, Sabine. Dual role of the antioxidant enzyme peroxiredoxin 6 in skin carcinogenesis. Cancer Research 2013; 73: 3460-3469

Rongioletti, Franco; Merlo, Giulia; Cinotti, Elisa; Fausti, Valentina; Cozzani, Emanuele; Cribier, Bernard; Metze, Dieter; Calonje, Eduardo; Kanitakis, Jean; Kempf, Werner; Stefanato, Catherine M; Marinho, Eduardo; Parodi, Aurora. Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. Journal of the American Academy of Dermatology 2013; 69: 66-72

Rozati, Sima; Naef, Lukas; Levesque, Mitchell P; French, Lars E; Dummer, Reinhard. Real-life experience with pegylated interferon and conventional interferon in adjuvant melanoma therapy. Journal of Immunotherapy 2013; 36: 52-56

Rüeff, Franziska; Przybyla, Bernhard; Bíló, Maria Beatrice; Müller, Ulrich; Scheipl, Fabian; Seitz, Michael J; Aberer, Werner; Bodzentya-Lukaszyk, Anna; Bonifazi, Floriano; Campi, Paolo; Darsow, Ulf; Haeberli, Gabrielle; Havranek, Thomas; Küchenhoff, Helmut; Lang, Roland; Quercia, Oliviero; Reider, Norbert; Schmid-Grendelmeier, Peter; Severino, Maurizio; Sturm, Gunter Johannes; Treudler, Regina; Wüthrich, Brunello. Clinical effec-
tiveness of hymenoptera venom immunotherapy: a prospective observational multicenter study of the European academy of allergology and clinical immunology interest group on insect venom hypersensitivity. PLoS ONE 2013; 8: e63233

Saulite, I; Volykov, B; Mehra, T; Hoetzenecker, W; Guenova-Hötzenecker, E. Incidental finding of lamellar calcification of the falx cerebri leading to the diagnosis of gorlin-goltz syndrome. Case Reports in Dermatology 2013; 5: 301-303


Stadler, Rudolf; Assaf, Chalid; Klemke, Claus-Detlev; Nashan, Dorothee; Weichenthal, Michael; Dummer, Reinhard; Sterry, Wolfram. Brief S2k guidelines - Cutaneous lymphomas. JDDG - Journal der Deutschen Dermatologischen Gesellschaft 2013; 11: 19-28, 20

Tissot, Alain C; Spohn, Gunther; Jennings, Gary T; Shamshiev, Abdiyapar; Kurrer, Michael O; Windak, Renata; Meier, Marco; Viest, Miriam; Hersberger, Martin; Kündig, Thomas M; Ricci, Romeo; Bachmann, Martin F. A VLP-based vaccine against interleukin-1beta protects mices from atherosclerosis. European Journal of Immunology 2013; 43: 716-722


Viard-Leveugle, Isabelle; Gaide, Olivier; Jankovic, Dragana; Feldmeyer, Laurence; Keri, Katrin; Pickard, Chris; Roques, Stéphanie; Friedmann, Peter S; Contassot, Emmanuel; French, Lars E. TNF-alpha and IFN-gamma are potential inducers of Fas-mediated keratinocyte apoptosis through activation of inducible nitric oxide synthase in toxic epidermal necrolysis. Journal of Investigative Dermatology 2013; 133: 489-98

Vlieg-Boerstra, B J; van de Weg, W E; van der Heide, S; Skypala, I; Bures, P; Hallmer-Weber, B K; Hoffmann-Sommergruber, K; Zauli, D; Ricci, G; Dubois, A E J. Additional indications for the low allergenic properties of the apple cultivars Santana and Elise. Plant Foods for Human Nutrition 2013; 68: 391-395

von Moos, Seraina; Graf, Nicole; Johansen, Pål; Müllner, Gerhard; Kündig, Thomas M; Sentí, Gabriela. Risk assessment of Hymenoptera re-stinging frequency: implications for decision-making in venom immunotherapy. International Archives of Allergy and Immunology 2013; 160: 86-92

Voskens, Caroline J; Goldinger, Simone M; Loquai, Carmen; Robert, Caroline; Kaehler, Katharina C; Berking, Carola; Bergmann, Tanja; Bockmeyer, Clemens L; Eigentler, Thomas; Fluck, Michael; Garbe, Claus; Gutzmer, Ralf; Grabbe, Stephan; Hauschild, Axel; Hein, Rüdiger; Hundorfan, Gheroge; Justich, Armin; Keller, Ullrich; Klein, Christina; Mateus, Christine; Mohr, Peter; Paetzold, Sylvie; Satzger, Imke; Schadendorf, Dirk; Schlaeppi, Marc; Schuler, Gerold; Schuler-Thurner, Beatrice; Trefzer, Uwe; Ulrich, Jens; Vaubel, Julia; von Moos, Roger; Weder, Patrik; Wilhelm, Tabeta, Göppner, Daniela; Dummer, Reinhard; Heinzerling, Lucie M. The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS ONE 2013; 8: e53745

Waeeckerle-Men, Ying; Bruffaerts, Nicolas; Liang, Yuan; Jurion, Fabienne; Sander, Peter; Kündig, Thomas M; Huygen, Kris; Johannsen, Pål. Lymph node targeting of BCG vaccines amplifies CD4 and CD8 T-cell responses and protection against Mycobacterium tuberculosis. Vaccine 2013; 31: 1057-1064

Waeeckerle-Men, Ying; Mauracher, Andrea; Häkerud, Monika; Mohanan, Deepa; Kündig, Thomas M; Hagset, Anders; Johansen, Pål. Photochemical targeting of antigens to the cytosol for stimulation of MHC class-I-restricted T-cell responses. European Journal of Pharmaceutics and Biopharmaceutics 2013; 85: 34-41

Walter, Anne; Schäfer, Matthias; Cecconi, Virginia; Matter, Claudia; Urosevic-Maïwald, Mirjana; Belloni, Benedetta; Schönewolf, Nicola; Dummer, Reinhard; Bloch, Wilhelm; Werner, Sabine; Beer, Hans-Dietmar; Knuth, Alexander; van den Broek, Maries. Aldara activates TLR7-independent immune defence. Nature Communications 2013; 4: 1560


Widmer, Daniel S; Hoek, Keith S; Cheng, Phil F; Eichhoff, Ossia M; Biedermann, Thomas; Raaijmakers, Marieke I G; Hemmri, Silvio; Dummer, Reinhard; Levesque, Mitchell P. Hypoxia contributes to melanoma heterogeneity by triggering HIF-1alpha-dependent phenotype switching. Journal of Investigative Dermatology 2013; 133: 2436-2443

Wüthrich, Brunello; Schmid-Grendelmeier, Peter; Schindler, Christian; Imboden, Medea; Bircher, Andreas; Zemp, Elisabeth; Probst-Hensch, Nicole. Prevalence of atopy and respiratory allergic diseases in the elderly SAPALDIA population. International Archives of Allergy and Immunology 2013; 162: 143-148

Reviews


Ballmer-Weber, B; Spring, Ph; Bircher, A; Simon, D. Handekzeme: praktisches Vorgehen in Diagnostik und Behandlung. Swiss Medical Forum = Schweizerisches Medizin-Forum 2013; 23: 453-458

Bosshard, Philipp P; Graf, Nicole; Knaute, Damaris Fröhlich; Kündig, Thomas; Lautenschlager, Stephan; Weber, Rainer. Response of treponema pallidum particle agglutination test titers to treatment of syphilis. Clinical Infectious Diseases 2013; 56: 463-464

Bühler, M N; Feldmeyer, L; Wüthrich, R P; French, L E; Djamei, V; Serra, A L; Hofbauer, G F L. Die edukative Website Dermaguard zur Prävention von Hautkrebs nach Organtransplantation. Praxis 2013; 102: 1415-1420

de Monchy, J G; Demoly, P; Akdis, C A; Cardona, V; Papadopoulos, N G; Schmid-Grendelmeier, P; Gayraud, J. Allergology in Europe, the blueprint. Allergology 2013; 68: 1211-1218

de Waard-van der Spek, Flora B; Andersen, Klaus E; Darsow, Ulf; Mortz, Charlotte G; Orton, David; Worm, Margitta; Muraro, Antonella; Schmid-Grendelmeier, Peter; Grimalt, Ramon; Spiewak, Radoslaw; Rudziveiciene, Odiilla; Flohr, Carsten; Halken, Susanne; Ficchi, Alessandro; Borrego, Luis M; Oranje, Arnold P. Allergic contact dermatitis in children: which factors are relevant? (review of the literature). Pediatric Allergy and Immunology 2013; 24: 321-329

Dreier, Jil; Felderer, Lea; Barysch, Marjam; Rozati, Sima; Dummer, Reinhard. Basal cell carcinoma: a paradigm for targeted therapies. Expert Opinion on Pharmacotherapy 2013; 14: 1307-1318


Dummer, Reinhard; Rozati, Sima; Guenova-Hötzeenecker, Emmanuella; Cozzio, Antonio. Less can be more: the impact of chemotherapy on cutaneous T-cell lymphomas. Future Oncology (London, England) 2013; 9: 1061-1064

Franzen, Daniel; Schad, Karin; Dummer, Reinhard; Russi, Erich W. Severe acute respiratory distress syndrome due to ipilimumab. European Respiratory Journal 2013; 42: 866-868


Gassner, Markus; Gehrig, Regula; Schmid-Grendelmeier, Peter. Hay fever as a Christmas gift. New England Journal of Medicine 2013; 368: 393-394

Gisler, Valentin; Schaer, Dominik; Wichmann, Werner; Kerl, Katrin; Franzen, Daniel. Kein tropisches, aber ein nicht minder exotisches Fieber. Praxis 2013; 102: 999-1003


Hafner, J. La Société suisse de Dermatologie et de Vénéréologie SSDV fête ses 100 ans : Un jubilé attestant d’une histoire et d’une performance impressionnantes. Schweizerische Ärztezeitung (SÄZ) 2013; 1428

Hafner, J; Bonini, S. “In der Gesellschaft herrscht ein positiver Wind”. Dermatologie Praxis 2013; 18-19

Haliasos, Elena C; Kerner, Miryam; Jaimes, Natalia; Zalaudek, Iris; Malvehy, Josep; Hofmann-Wellenhof, Rainer; Braun, Ralph P; Marghoob, Ashfaq A. Dermoscopy for the Pediatric Dermatologist Part III: Dermoscopy of Melanocytic Lesions. Pediatric Dermatology 2013; 30: 281-293

Haliasos, Elena C; Kerner, Miryam; Jaimes, Natalia; Zalaudek, Iris; Malvehy, Josep; Lanschuetzer, Christoph M; Hinter, Helmut; Hofmann-Wellenhof, Rainer; Braun, Ralph; Marghoob, Ashfaq A. Dermoscopy for the pediatric dermatologist, part ii: dermoscopy of genetic syndromes with cutaneous manifestations and pediatric vascular lesions. Pediatric Dermatology 2013; 30: 172-181

Haliasos, Elena C; Kerner, Miryam; Jaimes-Lopez, Natalia; Rudinicka, Lidia; Zalaudek, Iris; Malvehy, Josep; Hofmann-Wellenhof, Rainer; Braun, Ralph P; Marghoob, Ashfaq A. Dermoscopy for the pediatric dermatologist part I: dermoscopy of pediatric infectious and inflammatory skin lesions and hair disorders. Pediatric Dermatology 2013; 30: 163-171


Kistowska M1, Gehrke S1, Jankovic D1, Kerl K1, Fettelschoss A1, Feldmeyer L1, Fenini G1, Kolios A1, Navarini A1, Ganczucievic R2, Schauber J3, Contassot E1, French LE1 IL-1β drives inflammatory responses to propionibacterium acne in vitro and in vivo. J Invest Dermatol 2014 Mar; 134: 677-85


BRAFV600K mutation-positive melanoma (BRIM-3): extended
A. Safety and efficacy of vemurafenib in BRAFV600E and
JA, Flaherty KT, Yin M, Caro I, Cheng S, Trunzer K, Hauschild
D, O'Day SJ, Kirkwood JM, Eggermont AM, Dréno B, Sosman
2014; 50: 774-783

Lenggenhager D, Curioni-Fontecedro A, Storz M, Shakhova O,
Sommer L, Widmer DS, Seifert B, Moch H, Dummer R, Mi-
hic-Probst D. An Aggressive Hypoxia Related Subpopulation
of Melanoma Cells is TRP-2 Negative. Transl Oncol 2014; 7: 206-12

Liu M, Johansen P, Zabel F, Leroux JC, Gauthier M. Semi-per-
meable coatings fabricated from comb-polymers efficiently

McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB,
Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, Garbe C,
Testori A, Maio M, Lorigan P, Lebbé C, Jouary T, Schadendorf
D, O'Day SJ, Kirkwood JM, Eggermont AM, Dréno B, Bosman
JA, Flaherty KT, Yin M, Caro I, Cheng S, Trunzer K, Hauschild
A. Safety and efficacy of vemurafenib in BRAFV600E and
BRAFV600K mutation-positive melanoma (BRIM-3): extended
follow-up of a phase 3, randomised, open-label study. Lancet
Oncol 2014; 15: 323-32

McCusker M1, Basset-Seguin N2, Dummer R3, Lewis K4,
Schadendorf D5, Sekulic A6, Hou J7, Wang L7, Yue H7,
Hauschild A8. Metastatic basal cell carcinoma: Prognosis de-
pendent on anatomic site and spread of disease. Eur J Cancer
2014; 51: 1008-25

Le TM, Kummeling I, Dixon D, Barreales LT, Ballmer-Weber,
BK, Clausen M, Gowland MH, Majkowska–Wojciechowska B,
Mustakov T, Papadopoulos NG, Knust AC, Potts J, Stukas R,
Burney P. Low preparedness for food allergy as perceived by
school staff: a EuroPrevall survey across Europe. J Allergy Clin

Nägeli M, Fasshauer M, Sommerfeld J, Fendel A, Brandi G,
Stover JF. Prolonged continuous intravenous infusion of the
dipeptide L-alanine-L-glutamine significantly increases
plasma glutamine and alanine without elevating brain gluta-
mate in patients with severe traumatic brain injury. Crit Care
2014; 18: R139

Nägeli MC, Dummer R. Vismodegib (Erivedge®). Schweiz Med
Forum 2014; 14: 284-286

Nobbe S, Hafner J. [Martorell Hypertensive Ischaemic Leg
Ulcer]. Zentral Bl Chir 2014 [Epub ahead of print]

Robert C, Karaszewska B, Schachter J, Rutkowski P, Mack-
iewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange
F, Mortier L, Chiarion-Sileni V, Drucis K, Krajsova I, Hauschild
A, Martin AM, Sun P, Crist W, Legos J, Rubin SD, Little SM,
Schadendorf D. Improved Overall Survival in Melanoma with
[Epub ahead of print]

Rodon J, Tawbi HA, Thomas AL, Stoller R, Turtschi CP, Baselga
J, Sarantopoulos J, Mahalingam D, Shou Y, Moles MA, Yang L,
Granvil C, Hurh E, Rose KL, Amayke DD, Dummer R, Mita AC.
A Phase 1, Multicenter, Open-Label, First-in-Human, Dose-Es-
calation Study of the Oral Hedgehog Inhibitor Sonidegib
(LDE225) in Patients With Advanced Solid Tumors. Clin Cancer
Res 2014; 20: 1900-1909

Rosezi S, Kempf W, Osterheer-Michaelis S, Bode-Lesniewska
B, Zimmermann DR, Dummer R, Cozzio A. Cutaneous Diffuse
Large B-Cell Lymphoma, Leg Type, With Bilateral Intraocular
Involvement and Infiltration to the CNS. J Clin Oncol 2014
[Epub ahead of print]

Schadendorf D, Amonkar MM, Milhem M, Grotzinger K, Dem-
idov LV, Rutkowski P, Garbe C, Dummer R, Hassel JC, Wolter
P, Mohr P, Trefzer U, Lefeuvre-Plesses C, Rutten A, Steven N,
Ullenham G, Sherman L, Wu FS, Patel K, Casey M, Robert C.
Functional and symptom impact of trametinib versus chemo-
therapy in BRAF V600E advanced or metastatic melanoma:
25: 700-6

Schäfer M, Willrodt AH, Kurinna S, Link AS, Farwanah H,
Geusau A, Gruber F, Sorg O, Huebner AJ, Roop DR, Sandhoff K,
Saurat JH, Tschachler E, Schneider MR, Langbein L, Bloch W,
Beer HD, Werner S. Activation of Nrf2 in keratinocytes causes
chloracne (MADISH)-like skin disease in mice. EMBO Mol Med
2014; 6: 442-57

Schilling B, Sondermann W, Zhao F, Griewank KG, Livingstone
E, Sucker A, Zelha B, Weide B, Trefzer U, Wilhelm T, Loquai C,
R, Goldinger SM, Zimmer L, Paschen A, Hillen U, Schaden-
dor D; DeCOG. Differential influence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efficacy in melanoma. Ann Oncol 2014; 25: 747-53

Schlapbach C, Gehad A, Yang C, Watanabe R, Guenova-Hötzelenecker E, Teague JE, Campbell L, Yawalkar N, Kupper TS, Clark RA. Human TH9 cells are skin-tropic and have autocrine and paracrine proinflamatory capacity. Sci Transl Med 2014; 6: 219ra8


Akdis CA, Crameri R, Akdis M. Immune regulation by intralymphatic immunotherapy with modular allergen translocation MAT vaccine. Allergy 2014; 69: 1162-70


Braun RP1, Marghoob A2. High-Dynamic-Range Dermoscopy Imaging and Diagnosis of Hypopigmented Skin Cancers. JAMA Dermatol. 2014 [Epub ahead of print]


Gehrke S1, Otsuka A1, Huber R1, Meier B1, Kistowska M1, Fenini G1, Cheng P1, Dummer R1, Kerl K1, Contassot E2, French LE1. Metastatic melanoma cell lines do not secrete IL-1β but promote IL-1β production from macrophages. J Dermatol Sci 2014; 74: 167-9

Gnädinger M, Schmid-Grendelmeier P. Symptomatische Therapie der allergischen Rhinokonjunktivitis. ARS MEDICI 2014; 5: 277-82


Guenova-Hötzeneccker E, Hoetzenecker W. Wie lassen sich die Erscheinungsbilder richtig diagnostizieren und behandeln? Dermatologie Praxis 2014; 24: 1


Hofbauer GF, Seçkin D, Gjersvik P, Bouwes Bavinck JN. Skin care in organ transplant patients europe meeting report from annual meeting, leiden, the Netherlands, 15-18 may 2014. J Invest Dermatol 2014; 134: 2861-3

Huber C1, French LE, Hafner J. Response to letter to the editor on skin manifestations of celiac disease: not always dermatitis herpetiformis. Int J Dermatol 2014; 53: e383-4


Reviews


Braun RP1, Marghoob A2. High-Dynamic-Range Dermoscopy Imaging and Diagnosis of Hypopigmented Skin Cancers. JAMA Dermatol. 2014 [Epub ahead of print]


Läuchli S. Tipps und Tricks für die Praxis. Dermatologie Praxis 2014; 24: 21-26

Läuchli S. Es gibt keine schnellen Therapieerfolge in der Behandlung von Narben. Dermatologie Praxis 2014; 24: 2-3

Läuchli S. Mohs-Chirurgie. Optimale Radikalität und Ästhetik in der Behandlung von Hauttumoren. SZD 2014; 4: 3-6

Läuchli S, Riess C. Nagelextraktion ist „out“. Der Allgemeinarzt 2014; 8: 34-36

Läuchli S, Riess C. Eingewachsene Zehennägel. Ars Medici 2014; 24: 1238-1240


Nobbe S. Kutane Vaskulitis – Übersicht für die Praxis. Praxis Dermatologie 2014; 24: 12-17


Schmid-Grendelmeier P. Atopische Dermatitis und Pruritus im Alter. DERMATOLOGIE PRAXIS 2014; 2: 4

Schmid-Grendelmeier P. Augen auf bei Insektenstichen. Sprechstunde Doktor Stutz 2014; 3: 16


